INNOVATION PROJECTS SKOLKOVO FOUNDATION
BIOMEDICAL TECHNOLOGIES CLUSTER 12 14 14 15
119
2 CONTENTS
ABOUT THE FOUNDATION 5 Mission 6 Goals 7 Ecosystem 7 Benefits and opportunities for participants 8
Key numbers and facts 10
Skolkovo industrial partners: first success stories 11
BIOMEDICAL TECHNOLOGIES CLUSTER 12
14 About the Cluster
14 Innovation Priorities
15 Achievements
PROJECTS OF PARTICIPATING COMPANIES BROKEN DOWN BY INNOVATION PRIORITIES 17
119 CLUSTER CONTACTS
PROJECTS OF PARTICIPATING COMPANIES IN ALPHABETICAL ORDER 123
3 4
Mission 6 Goals 7 Ecosystem 7 Benefits and opportunities for participants 8
Key numbers and facts 10
Skolkovo industrial partners: first success stories 11
ABOUT THE FOUNDATION 5 MISSION OF THE SKOLKOVO FOUNDATION
THE SKOLKOVO INNOVATION CENTER WAS ESTABLISHED BY FEDERAL LAW NO. 244 DATED SEPTEMBER 28, 2010 «ON THE SKOLKOVO INNOVATION CENTER» AS THE COUNTRY’S RESPONSE TO THE NEW CHALLENGES OF THE GLOBAL ECONOMY: ACCELERATING TECHNOLOGICAL PROGRESS AND RISING COMPETITION FOR KNOWLEDGE AND COMPETENCIES BETWEEN LEADING NATIONS.
Space Technology and Telecommunications
Nuclear Technologies
Information Technologies
The mission of the Skolkovo Innovation Center, and the Skolkovo Foundation that established it, is to create an ecosystem in Russia conducive to the development of innovations to support cutting edge Energy Efficiency research and development and then to commercialize the results of such R&D in five priority fields of technological progress.
Biomedical Technologies
education and R&D experimental design and commercialization research of the results
The Skolkovo Foundation aims to ensure that The Skolkovo Foundation is creating a model the Innovation Center can provide facilities for for the development of an innovation-based the full cycle of the innovation process including economy for all of Russia. The Innovation Center education, R&D, experimental research and serves as proving grounds to test the mechanisms design, and commercialization of the results.. for promoting the practical application of cutting edge ideas proposed by Russian academic and applied research institutions.
SKOLKOVO IS A KEY ELEMENT IN THE SYSTEM OF RUSSIAN DEVELOPMENT INSTITUTES THAT seeks to support innovation projects at every stage of development, from when it’s just an idea all the way through sales and marketing, creating a system of continuous support that startups can draw upon as they work on their projects. The Skolkovo Foundation focuses on the pre-seed and seed stages of business development and some of the aspects of the launch stage. Subsequent stages such as business growth and development, IPO and financing are supported by RVK, RUSNANO and VEB, respectively.
6 SKOLKOVO’S GOAL IS TO CREATE AN INNOVATION ECOSYSTEM CONDUCIVE TO RESEARCH AND ENTREPRENEURSHIP
ESTABLISHING AN INNOVATION ECOSYSTEM INCLUDES CREATING AND DEVELOPING EDUCATIONAL, RESEARCH AND ENTREPRENEURIAL ENVIRONMENTS, AS WELL AS THE PHYSICAL INFRASTRUCTURE OF THE SKOLKOVO INNOVATION CENTER.
The ecosystem consists of the following key elements: startups, R&D centers of the industrial partners, venture capital investors, the Technopark, the Skolkovo Institute of Science and Technology (Skoltech) and the infrastructure, i.e. the town of Skolkovo.
SKOLKOVO ECOSYSTEM
PARTICIPANTS The kernel of the ecosystem, early-stage high tech startup companies that have been given the status of Skolkovo project EDUCATIONAL participants. ENVIRONMENT Skoltech, OpUS, international and Russian partner universities. PARTNERS Industrial partners (major international and Russian companies), accredited VC investors.
TECHNOPARK Laboratory and research infrastructure.
Infrastructure of Skolkovo Open University Skolkovo. Innovation Center.
7 BENEFITS AND OPPORTUNITIES FOR PARTICIPANTS
TAX AND CUSTOMS BENEFITS:
• Social tax* — 14% • Income tax — 0% • VAT — 0% • Property tax — 0% • Customs tariffs on imported research equipment Insurance premiums paid by the employer — 0%
GRANT SUPPORT
ACCESS TO INFRASTRUCTURE AND CONSULTING:
• R&D infrastructure and common use centers, consultations for applicants for Skolkovo participant status, office leases • International and national events • Education and mentoring (OpUS, Skoltech)
HELP WITH RAISING FINANCE AND ACCELERATION: • VC and angel investors • Infrastructure and technologies offered by industrial partners
HOW TO BECOME A PARTICIPANT:
APPLICANTS APPLICANT SKOLKOVO FOUNDATION EXPERT PANELS PARTICIPANT STATUS 01 02 03 IS GRANTED TO THE fills out the online assesses the application based assess the project in detail APPLICANT form at www.sk.ru on formal criteria: a) Is it feasible in principle? а) Have all the necessary b) What significant information and documents advantages does it offer over been provided? foreign competitors? b) Is the applicant a Russian c) What is its legal entity? commercialization potential? с) Does the applicant meet d) Does the project team have the technology criteria of the the requisite experience to Skolkovo Foundation? successfully implement the project on the international level? 10 randomly selected experts from a large pool of experts
~ one month
8 KEY PRINCIPLES FOR GRANT FINANCING BY THE SKOLKOVO FOUNDATION
Grant Amount Co-Financing Terms
A business plan and Idea an R&D program are developed, the market is Up to100% researched and a search Skolkovo for investors is initiated
More than A working prototype 25% Seed is manufactured, Co-investor a technical design Up to is developed and the 75% concept is tested Skolkovo
Up to Early R&D is completed, an 50% stage industrial prototype is Skolkovo developed and pre-clinical More than trials and phase I clinical 50% trials are conducted Co-investor
Advanced stage R&D and clinical trials are Up to 25% completed, pilot batches Skolkovo are manufactured and More than 75% trialed Co-investor
HOW FINANCING IS ALLOCATED
The participant prepares a The participant submits The Foundation’s Preparation for a presentation in accordance the grant memorandum services check the meeting of the Grant with the recommended with appendixes application and have Committee format and submits it via it audited by external sk.ru experts
10 days no more than 90 (+10) days ~ 1,5 months ~ 2 weeks
The Foundation decides The Foundation The participant is The Grant Committee whether the presentation checks whether all the notified of the results of decides whether to will be reviewed necessary information the review award a grant and documents have been submitted
APPLICATION GRANT REVIEW BY THE GRANT MEMORANDUM FOUNDATION COMMITTEE
PROJECT NEEDS MORE REFUSAL WITH WORK (A MINI-GRANT MAY OR EXPLANATION BE GIVEN )
9 KEY NUMBERS AND FACTS
bln 6873 4,3 RUB 1147 applications firm commitments participating companies for the Participant of the accredited from 49 regions status investors on financing of the country of the Participants:
bln 1288 43,6 RUB 13 500 intellectual Participants’ work places property earnings applications
bln bln 500 10,6 RUB 11,1 RUB patents approved private and certificates grants volume investment volume
as of May, 2015
10 и нду Стриа Льные партнеры
ВАЖНЫМ НАПРАВЛЕНИЕМ ВЗАИМОДЕЙСТВИЯ «СкоЯВЛЯЕТСЯ ОБЕСПЕЧЕНИЕЛ Зково»АПОЛНЕНИЯ ОФИСН О- — первые у Спехи ИССЛЕДОВАТЕЛЬСКИХ ОБЪЕКТОВ И БЫТОВОЙ SKOLKOVOИНФРАСТРУКТУРЫ ИННОВАЦИОННО ГINDUSTRIALО ЦЕНТРА. ИНВЕСТОРЫ и ндустриальные партнеры размещают центры ниокр в «Сколково» и выступают заказчиком PARTNERSи потребителем инновационных - FIRST решений ACHIEVEMENTS стартапов – тем самым они интегрируют исследовательскую и бизнес-среду инновационной системы «Сколково». TheВ рамках industrial «тонкой partners» настройки place стратегии the R&D развития centres инно -in Skolkovo and act as the Customer and Consumer ofвационного the start-ups’ центра особое innovative внимание solutions уделяется thusразви -integrating the research environment and business environmentтию экосистемного of the взаимодействия Skolkovo innovative с индустриальными system. И МЕНТОРЫ партнерамикЛ ючевые. преимуще Ства Сотрудниче Ства Со « Ско Лково» д ЛЯ отра СЛевых Преждепартнеров всего это поддержка партнеров в создании KEYрабочих ADVANTAGES мест, формировании OF COOPERATION необходимых исследова WITH- SKOLKOVO FOR INDUSTRY PARTNERS СОЗДАВАЯ•тельских ИННОд оступВ компетенцийАЦИИ к –лучшим2015 и привлечении кадрам инвестиций и передовой в соз- российской науке – «Сколково» является даниепривлекательным исследовательской инфраструктуры местом центровдля работы и центром притяжения лучших специалистов из •НИОКР Access партнеров to the. bestРабочие staff места and в центрахcutting-edge НИОКР Russian science – the Skolkovo is the attractive place ...составятofдругих employment не менее городов четверти and the ивсех м attraction рабочихосквы. мест centre of the best experts from Moscow and other cities. ••экосистемы Convenienceудобство. проведенияof research and исследований experiments based и экспериментовon concentration of сprocess учетом and конце humanнтрации ...Ещеresources,технологических одним приоритетным cooperation направлением и людскихwith Skolkovo взаимодей ресурсов, - Institute сотрудничестваof Science and Technologies со Сколковск (SkolTekh),им институтом ...ствияdedicated с индустриальными Russian institutes, партнерами theявляется Skolkovo обес- partners. печениенауки заполнения и технологии офисно-исследовательских (Сколтех), профильными российскими институтами, партнерами • Access«Сколково». to advanced technologies being created by start-ups, the Skolkovo residents, including ...объектовwith state и социально support.-бытовой инфраструктуры инно- вационного центра. ВАЖНЫМ НАПРАВЛЕНИЕМ ВЗАИМОДЕЙСТВИЯ •• Simplificationд оступ к передовым of ministerial технологиям,procedures, absence создаваемым of bureaucratism стартапами, and red tape. резидентами «Сколково», ПАРРяд крупныхТН индустриальныхЕРЫ партнеров уже размести- ЯВЛЯЕТСЯ ОБЕСПЕЧЕНИЕ ЗАПОЛНЕНИЯ ОФИСНО- • Taxв том and числеcustoms при concessions государственной as for the Skolkovo поддержке. participating companies. лись на территории инновационного центра – это ИССЛЕДОВАТЕЛЬСКИХ ОБЪЕКТОВ И БЫТОВОЙ •«Камаз упрощение», Росатом, « Даурияадминистративных», «Татнефть», «Техносерв процедур,». отсутствие бюрократизма и волокиты. «С•КОЛОбщие н алоговые площадиК центровОВО и таможенные НИОКР», запланированных льготы, для как дляИН Фкомпаний-участниковРАСТРУКТУРЫ ИННОВАЦИ «СколОННОково».ГО ЦЕНТРА. ИНВЕСТОРЫ размещения на территории Инновационного центра, со- индуставляют Соколотриа 130 Лтысячьные м 2партнеры. фонда «Ско Лково» Сегодн Я
PARTNERSHIP INDUSTRIAL компанийWithin индустриальных theВ рамках Innovation «тонкой Centre »партнеров настройки development стратегии strategy развития инно- >4060 “fine tuning”,вационного special attentionцентра особое is paid to внимание development уделяется разви- of the ecosystemтию экосистемного interaction withвзаимодействия industrial partners. с индустриальными industrial companies became First of all, this is the partners’ support in creation И МЕНТОРЫ о ценка численностипартнерами сотрудников. в центрах ниокр the Foundation partners of work places, forming of the required research >3 500 на 2015competencies г, чел.Прежде and всего attraction это поддержка of investment партнеров into в создании 2 человек260 ths m creationрабочих of the местpartners’, формировании R&D centres необходимых research исследова- area for R&D infrastructure.тельских Jobs компетенций at R&D centres и привлечении will account forинвестиций в соз- centres о ценкаat leastсуммарного даниеa quarter исследовательской of бюджета all jobs within ниокр the инфраструктуры ecosystem. до конца 2015 центров г. Population of the office and research facilities, as НИОКР партнеров. Рабочие места в центрах НИОКР >33 well as accommodation within the innovation centre 2 0 млрд49 руб. is anotherсоставят priority не areaменее in четверти cooperation всех withрабочих the мест industrial partners will industrialэкосистемы partners. . establish R&D centres A numberЕще of одним industrial приоритетным partners, including направлением Kamaz, взаимодей- 1 Rosatom,ствия Dauria, с индустриальными Tatneft and Tekhnoserv, партнерами already является обес- have offices in the Innovation Centre. The total area 5 5000 печение заполнения офисно-исследовательских employees in R&D of R&D centres planned to be set up within the - - centres Innovationобъектов Centre иisсоциально approximatelyбытовой 130 инфраструктурыthousand инно m2. вационного центра. Ряд крупных индустриальных партнеров уже размести- лись на территории инновационного центра – это «Камаз», Росатом, «Даурия», «Татнефть», «Техносерв». Общие площади центров НИОКР, запланированных для размещения на территории Инновационного центра, со- ставляют около 130 тысяч м 2. ПАРТНЕРСТВО ИНДУСТРИАЛЬНОЕ 60 индустриальных компаний стали партнерами Фонда
тысяч м 2 11 260 площадь для центров НИОКР
2 0 49 11 индустриальных партнеров разместят центры НИОКР 1
5 5000 сотрудников в центрах НИОКР
11
14 14 15
12
14 about the cluster
14 innovation priorities
15 achievements ABOUT THE CLUSTER 13 ABOUT THE CLUSTER
The Cluster’s goal is to create a competitive biomedical technologies industry while bearing in mind that, in addition to trying to maximize revenue, we’re making a decisive contribution to improving the nation‘s health. Our efforts have led to a significant increase in the number of companies seeking to commercialize science and biomedical technologies. As we try to promote this growth, we are seeing that the goal of the companies in our sector is improving healthcare. A healthy nation is a productive nation. Our mission is to support the development of biomedical technologies for a healthy and wealthy Russia. KIRILL KAEM Vice President, Executive Director of the BioMedical Technologies Cluster of the Skolkovo Foundation
INNOVATIVE PRIORITIES
• MEDICAL AND THERAPEUTICAL DEVICES AND BIOMATERIALS
• DRUG DISCOVERY & DEVELOPMENT
• OMICS BIOLOGY & COMPUTATIONAL BIOLOGY
• CELL & TISSUE TECHNOLOGIES
BIOTECHNOLOGIES IN AGRICULTURE AND INDUSTRIAL BIOTECHNOLOGY PLANT AGRICULTURE:
• LIVESTOCK AND AQUACULTURE INNOVATIONS
• INDUSTRIAL MICROBIOLOGY AND BIOTECHNOLOGY
• INNOVATIONS IN PROCESSING OF AGRICULTURAL PRODUCTS
• FORESTRY AND FOREST TECHNOLOGIES
14 ACHIEVEMENTS
The Cluster is aimed at creation of a competitive sector of biomedical technologies, and we must remember that in addition to the contribution to revenue growth, we are making a decisive contribution to improving the health of the nation. Results of our work are embodied in a significant increase in the number of companies focused on commercialization of science and biomedical technologies. Striving towards the support of this growth we convince that the objective of our companies’ work is health maintenance. Healthy Nation is a more productive nation at the same time. Our mission is to support the development and commercialization of biomedical technologies for healthy and rich Russia. KIRILL KAEM Vice-President, Executive Officer of Skolkovo Foundation Biomedical Cluster.
PERFORMANCE The Cluster contains over 230 innovative companies aimed at the implementation of projects in the field of innovative drugs, medical diagnostic and therapeutic products, new bio-compatible materials and products of cellular technologies. More than 800 jobs have already been created in these companies, the revenue of Cluster’s start-ups amounts to 2,815 million Roubles in 2014. The Cluster awarded 30 grants and 34 mini-grants (no more than 5 million Roubles) for scientific research activities. Residents of the Cluster achieve much success in their activities.
• Fusion Pharma held an international expert council focused on design of the first phase of clinical research of its innovative drug PF-114 developed to for the management of resistant forms of blood cancer.
• The First Oncology Research and Advisory Center (FORAC) won a tender at the largest world congress on personalized medicine ended in California. The Company is engaged in individual choice of drugs for patients based on their genetics, searches for new niches for use of known drugs and makes researches on ageing matters.
• ООО “BIND (RUS)”, BIND Therapeutics Inc. subsidiary, Cambridge, Massachusetts, USA. (NASDAQ: BIND), provided results of the second phase of clinical research of its drug BIND-014 for non-small cells lung cancer treatment. Examination of patients with NSCLC of planocellular histology revealed that the intermediate overall survival is 11.1 months.
• For the first time ever in the world, a resident of Skolkovo - Russian Laboratory 3D Bioprinting Solutions - printed an organ structure of the thyroid gland of the mouse on the domestic bioprinter .
• At the annual congress of the American Association for Cancer Research (AACR 2015) Russian company «Ruspharmtech», a resident of Skolkovo Foundation, presented the results of the pre-clinical study of the innovative drug Alofanib. Alofanib confirmed the effectiveness for ovarian cancer control.
• Impedance Medical Technologies Company, a grant-holder of Skolkovo Foundation, has developed the most effective device for screening women to detect mammary gland cancer - mammography based on electrical impedance tomography (EIT) - a method for studies of tissues and organs created on the basis of scientific developments of the Institute of Radio Engineering and Electronics named after V.A. Kotelnikov, Russian Academy of Sciences, Yaroslavl State Medical Academy and the Russian Scientific Center of Radiology and Nuclear Medicine.
• Within the framework of the St. Petersburg International Economic Forum, IBM, Skolkovo Foundation, and the First Oncology Research and Advisory Center (FORAC) have signed a memorandum on understanding. The document envisages forming a first of its kind strategic, technological and marketing partnership aimed at developing a platform of personalized medicine in Russia.
• NSL Company introduced its second development - portable laser perforator for contactless puncture of finger tissues when taking a blood sample for tests, during the largest European Expo of Lazer Technologies - Laser Photonics -2015. It is the most compact laser perforator with the weight of just over 100 grams. It enables to make over 100 punctures using one battery.
• Federal Service for Intellectual Property, Patents and Trademarks Regulations included the Aiviks molecule into TOP-100 inventions of Russia-2014.
15 16 PROJECTS OF PARTICIPATING COMPANIES BROKEN DOWN BY INNOVATION PRIORITIES
RUSBITECH, LLC
HARDWARE AND SOFTWARE COMPLEX - DETERMINATION OF EXTENSION OF MALIGNANT TUMORS WITH THE USE OF STREAMING SCREENING METHOD
COMPETITIVE ADVANTAGES / TEAM / The uniform screening system at leading • Ostrometsky I. — Director. cancer institutions of the country will allow PARTNERS: to increase the detection rate of cancer. At • RPA RusBITech, OJSC; the initial stage it is possible to equip more • Blokhin N. Cancer Research than 150 major medical institutions of the Centre of RAMS; IT HEALTHCARE MEDICAL PRODUCTS & EQUIPMENT, Russian Federation. • Ivanovo Medical Academy; • Yaroslavl Regional Oncology Centre; ESSENCE OF INNOVATION / Medical University (Graz, Austria); The developed hardware and software • Narimanov N. Azerbaijan Medical complex will be a centralized learning University (Baku, Azerbaijan). database of known tumors with the possibility of one-time connection of the required number of subscribers.
MARKET POTENTIAL / Market capacity of the project products in Russia by 2016 may be up to 10 thousand subscriber complexes; the price of one subscriber complex is 1.5 million rubles. Profit from the project can be up to 15 billion rubles during 2016-2025.
CONTACTS / Moscow +7 (495) 648 15 33 [email protected] www.rusbitech.ruu
19 PHARMASAPPHIRE, LLC
INNOVATIVE SAPPHIRE DOSING PUMPS FOR HIGHLY ACCURATE FILLING OF LIQUID PHARMACEUTICALS
COMPETITIVE ADVANTAGES / Unique wear resistance, increased chemical purity of drugs, increased drugs efficacy, significantly increased shelf life and storage time of drugs, vast sales markets, clean production, huge financial
MEDICAL PRODUCTS & EQUIPMENT, HEALTHCARE IT HEALTHCARE MEDICAL PRODUCTS & EQUIPMENT, and economic benefits.
ESSENCE OF INNOVATION / The company was the first in the world to utilize an advanced innovative material in the manufacture of plunger pairs from a single crystal sapphire. TEAM / MARKET POTENTIAL / • Savenkov A. — General Director, Use in the pharmaceutical, chemical, author of the project; petro-chemical, perfumery, cosmetic, • Mukhanov E. — Marketing food and other industries. By 2017 the and Sales Director; annual demand for dosing pumps will • Savenkova J. — Senior Project reach more than 4 billion US dollars only Manager. in pharmaceutical industry.
CONTACTS / Moscow +7 (676) 51 28 +7 (499) 140 87 48 [email protected] www.sapptech.ru
20 IK SOVREMENNIE TEHNOLOGII, LTD
SOLUBLE CAVA-FILTER
COMPETITIVE ADVANTAGES / • Elimination of the perforation possibility of the vena cava with resorption; • Elimination of the influence of epithelialization on the removal process;
• Exclusion of additional surgical IT HEALTHCARE MEDICAL PRODUCTS & EQUIPMENT, interventions for migration; • Expansion of good indications for implantation.
ESSENCE OF INNOVATION / Soluble cava filter and the method of delivery to the inferior vena cava TEAM / to prevent the pulmonary embolism (PE) • Gluschenko L. — CEO, at a floating deep venous thrombosis co-founder, practicing vascular surgeon, of lower extremities and recurrent a grad-uate student at Ulyanovsk State pulmonary embolism. All this calls for Univ. (UlSU); reduction the need for additional surgical • Sharifulov A. — Dr.Med.Sc., prof., interference. Head of R&D. Head of cardiology and Aims of the project: X-ray surgery development of Kazan • Cava filter is necessary as long as there Medical Academy; is a threat of separation of a thrombus; • Leibel O. — deputy dir. for business once the threat has passed, the filter dev., co-founder. Director of Technopark becomes a potential source “UlSU-High Technology”; of complications, such as the inferior • Okhotnikov O. — market consultant. vena cava syndrome. Head of R&D Center for Optoelectronics • We came up with the idea of creating Technology, Tampere Univ., Finland; a series of temporary soluble cava filters • Schepochkin V. — Ph.D, associate to prevent pulmonary embolism technologist. in a floating deep venous thrombosis of the lower extremity. • Reduced costs of treating the patient, for lack of need for re-operating (remove filter).
MARKET POTENTIAL / The cost of the dissolvable cava filter is equal to competing non-dissolvable filters. Moreover, hospitals could save $600 per patient of their budget (reduction of the rehabilitation period, no surgery to remove the filter). The cava filter will withstand pressures in the inferior vena cava (3 mm Hg) and dissolve in the blood stream for 90-180 days. CONTACTS / Ulianovsk region +7 (908) 484 19 04 [email protected]
21 SKOLKOVO GRANT
NСL, LLC
PROFESSIONAL MEDICAL LASER PERFORATOR FOR CONTACTLESS PUNCTURE OF FINGER TISSUES FOR BLOOD SAMPLING, AND PROTOTYPING OF A PEN-LIKE PERSONAL PERFORATOR
COMPETITIVE ADVANTAGES / Laser perforator is the only alternative to metal lancets providing absolute sterility, patient and medical staff
MEDICAL PRODUCTS & EQUIPMENT, HEALTHCARE IT HEALTHCARE MEDICAL PRODUCTS & EQUIPMENT, protection against infection, efficiency, and less painful puncture. Laser puncture technology is certified in the USA, Europe, Russia, China, Korea.
ESSENCE OF INNOVATION / Formation of a «microchannel» by evaporation of biological tissues with a 2940 nm laser. Absolute sterility, rapid healing, minimal pain. TEAM / MARKET POTENTIAL / • Savchuk E. — General Director; Potential market for the devices — • Polushkin V. — Technical Director. number of capillary blood collection stations.Total number of finger blood collection stations in Russia is ~ 45,000. The potential market for perforators (in producer prices) amounts to 2 billion RUB. Avg. lifetime is 5 years. Target market (10% of the potential market) is worth 40 million RUB per year. Consumables market (caps) is worth 20-30 million RUB per year. Total target market is worth 60-70 million RUB per year.
CONTACTS / Moscow, Troitsk +7 (903) 517 97 66 [email protected] www.ncl-medical.com
22 AELITA, LLC
UNIVERSAL ANESTHESIA WORKSTATION “ROSA”
COMPETITIVE ADVANTAGES / • Innovative injection technology of anesthetic dosing: anesthetic consumption is up to 2 times less; minimal side damage to a patient. • For all age groups of patients including infants;
• «Low-Flow» mode by semi-closed IT HEALTHCARE MEDICAL PRODUCTS & EQUIPMENT, and closed circuits; • Full digital design and control — up to full automation of anesthesia delivery in a near future. • Low cost: 45 000 USD (2 time less); • Fully adapted to developing counties conditions); • Cheap service); • Simple production. 10 billion rubles by 2016 (330 million USD). Stable significant grow of Russian ESSENCE OF INNOVATION / medical equipment market is partly Universal anesthesia workstation “ROSA” because of Government programs for is designed for inhalation anesthesia state clinics modernization but also is in combination with managed and auxiliary because of constantly growing demand artificial lung ventilation of adults and infants for medical services from population using all known gaseous and liquid volatile included paid ones. anesthetic agents including «Low-Flow» mode by semi-closed and closed circuits. TEAM / There is xenon anaesthesia in anesthesia • Smolyarov B., Ph.D.— Scientific leader, workstation «ROSA». Founder; • Goncharov Е. — Chief Engineer, major MARKET POTENTIAL / contributor to injector technology According to Russia custom 2 700 of anesthetic dosing; anesthesia machines were imported • Karpitski Y., Ph.D. — Marketing and in 2012. At the same time Russian Business Development; companies produce 150-200 anesthesia • Zolotarev A. — CEO. Has valuable machines per year. So, market volume for experience in innovation business, anesthesia machines was approximately and CFO experience in large companies; 2 900 units in 2012. • Borisov M. - Principal Design Engineer; At average price of anesthesia machine • Krupin A. - Production Director. of 1.7 million rubles (approx. 55 000 USD, data according to zakupki.gov.ru), money market volume is 4,9 billion rubles (160 million USD), with Russian manufactures share only for 5%. According to Production and Trade Ministry of Russia (Minpromtorg) Russian medical equipment market has been showing CONTACTS / significant grow. For 4 years before 2012 Nizhni Novgorod - Voronezh GAGR was 39% per year. +7 (987) 740 40 67 Expected GAGR for 2012-2016 is no less +7 (831) 424-22-04 than 15% per year and expected [email protected] anesthesia market volume is www.anekom.com
23 SKOLKOVO GRANT
BIOSOFT.RU, LLС
INFORMATION PLATFORM FOR BIOMEDICAL RESEARCH
COMPETITIVE ADVANTAGES / The platform under development will become a universal tool, which would allow to conduct all stages of research on the way from «omics data» to new targets, biomarkers and drugs. Currently there is no analogous product in the world
MEDICAL PRODUCTS & EQUIPMENT, HEALTHCARE IT HEALTHCARE MEDICAL PRODUCTS & EQUIPMENT, that could combine all of these functions.
ESSENCE OF INNOVATION / The main difference of the platform under development from similar software will be in the opportunity to conduct the whole cycle of research via only one integrated TEAM / tool. Besides standard algorithms, unique • Kel A. — leading scientist algorithms for search of key elements in in bioinformatics and molecular biology. cell pathways will be implemented in the Has big experience in systems biology platform. projects management; • Kolpakov F. — has highest competence MARKET POTENTIAL / in complex software development and The product is oriented on the management of groups of programmers; bioinformatics software market and on • Poroikov V. — has highest competence the market of systems biology services in methods of computer-aided search for outsourcing, such as search for new targets and in optimization of structures targets and biomarkers, drug repurposing and properties of pharmacological and personalized medicine. Currently the compounds. size of market the market is estimated at $3,39 bln. By 2020 it is expected to grow up to $9,18 bln.
CONTACTS / Novosibirsk [email protected] www.biosoft.ru [email protected]
24 SKOLKOVO GRANT
PHOTONICS, LLC
NEXT-GENERATION MINIMALLY INVASIVE LASER SURGICAL SYSTEM FOR MAINSTREAM MEDICINE AND DENTISTRY
COMPETITIVE ADVANTAGES / • Innovative medical technologies: TOR — automatic power control system; • LPM — coagulated micro columns; • M2 beam — creation of holes of smallest diameter and others.
The flexibility and the possibility IT HEALTHCARE MEDICAL PRODUCTS & EQUIPMENT, of modernization of the purchased equipment by purchasing additional modules. The compactness and the portability of system.
ESSENCE OF INNOVATION / An ultra-compact, low-cost laser platform for hard and soft tissue surgery based TEAM / on diode and DPSS laser technology • Selivanov V. — chief executive officer; with interchangeable clinical modules • Altshuler G. — project consultant, depending on the medical purpose. co-inventor, DScTech; A number of medical technologies • Shugailov I. — chief medical advisor, MD. confirmed with researches are used In laser system.
MARKET POTENTIAL / Target market segments include Minimally Invasive Surgical Instruments, Dental Equipment and Medical Aesthetic devices. The Minimally Invasive Surgical Instruments segment is expected to grow from $9.2 billion to $13.6 billion at a CAGR of 8.2%.
CONTACTS / Moscow +7 (495) 726 52 53 [email protected]
25 BIONOVA, LLС
REPLACEMENT AND REGENERATION OF BONE TISSUE
COMPETITIVE ADVANTAGES / Fully synthetic, high regenerative potential: bone defect organotypic replacement within 4-6 months, biocompatibility and non-immune responsiveness, optimal osteoporosis, architectonics is similar to trabecular bone tissue. MEDICAL PRODUCTS & EQUIPMENT, HEALTHCARE IT HEALTHCARE MEDICAL PRODUCTS & EQUIPMENT, ESSENCE OF INNOVATION / New technologies of production of ceramic materials are developed. The materials are capable of reaching necessary architectonics and metastable calcium orthophosphate microstructure TEAM / via chemical transformation. • Komlev V. - Director; • Churilov A. - General Director; MARKET POTENTIAL / • Barinov S. - Scientific constultant. Application: dentistry, reconstructive surgery, oncology. Market volumes in 2013 are estimated under 6,5 bn $. The market volumes forecast by 2016 is estimated under 9.6 bn $.
CONTACTS / Moscow +7 (495) 221 21 07 [email protected] osteonova.ru tricafor.ru
26 MILLISECOND TECHNOLOGIES, LLC
INNOVATIVE MST METHOD OF LOW-TEMPERATURE PASTEURIZATION / STERILIZATION OF LIQUID BIOMEDPHARMA PRODUCTS
COMPETITIVE ADVANTAGES / MST method can significantly reduce the processing temperature (less than 60 Co), and drastically reduce the exposure time
(less than 1 second), which largely solves IT HEALTHCARE MEDICAL PRODUCTS & EQUIPMENT, the problem of reliable and cost-effective to inactivate viruses without denaturation of useful proteins.
ESSENCE OF INNOVATION / The essence of innovation is to create a radically new technology gentle ultra-fast (millisecond) low-temperature pasteurization of liquid products while minimizing the denaturation of proteins and with a more powerful effect of inactivation.
MARKET POTENTIAL / TEAM / • Increased reliability inactivation by • Dolgopolov D. — project manager,CEO; increasing the safety of the original of • Gorodetsky V. — scientific consultant; useful properties; • Mislavsky B. — consultant for the • Principle minimal processing time at the commercialization of the project; lower temperature without the addition • Bubnov S. — investment advisor. of chemicals and irradiation; • Increased yield of useful proteins, cost reduction.
CONTACTS / Moscow [email protected]
27 SKOLKOVO GRANT
HEMACORE LABS, LLС
THROMBODYNAMICS-4D — A NEW INTEGRAL HEMOSTASIS ASSAY WITH A HIGH SENSITIVITY TO DISORDERS OF PLASMA AND PLATELET HEMOSTASIS
COMPETITIVE ADVANTAGES / • Estimation of the potential thrombotic risk in the early stages • sensitivity to all types of anticoagulant
MEDICAL PRODUCTS & EQUIPMENT, HEALTHCARE IT HEALTHCARE MEDICAL PRODUCTS & EQUIPMENT, drugs • Individual anticoagulant therapy planning. • high sensitivity to disorders of platelet hemostasis.
ESSENCE OF INNOVATION / Thrombodynamics-4D is the next generation of Thrombodynamics test, developed by HemaCore. Besides the standard parameters TEAM / of Thrombodynamics, Thrombodynamics- • Koltsov K. — CEO; 4D detects the spatial dynamics • Ataullakhanov F. — head of the research of thrombin propagation, this would make department, doctor of biological sciences, the test more informative, and will allow professor; to use it for the different pathologies • Panteleev M. — senior researcher, of blood coagulation. doctor of physical and mathematical sciences, PhD. of biological sciences. MARKET POTENTIAL / High sensitivity Thrombodynamics-4D to hypo — and hypercoagulability, the combination of physiological model of the study and the ability to measurement the spatial dynamics of thrombin propagation, makes method unique and competitive in the world market.
CONTACTS / Moscow +7 (495) 258 25 38 [email protected] www.hemacore.com
28 ALLIED INNOVATIONS, LLC
TEST-SYSTEM FOR CELLULAR HEMOSTASIS DIAGNOSTICS -TROMBOCYTEST
COMPETITIVE ADVANTAGES / TEAM / TROMBOCYTEST — a process and device • Kazaritsky V. - Genenral Director; for fast on-line detection of cell activity • Gabbassov Z. - Director for R&D; of patient’s whole blood without • Domogatsky S. - Director for Production. preliminary preparations, the designed lab-on-a-chip technology provides IT HEALTHCARE MEDICAL PRODUCTS & EQUIPMENT, global competitive strength and import substitution.
ESSENCE OF INNOVATION / TROMBOCYTEST — an invention of method and device for fast detection of hemostasis disturbances and assessment of risks of their progress, which provides high tech medical service at the point of care (POC).
MARKET POTENTIAL / The in-vitro diagnostics market of hematology and hemostasis has a good dynamics. It is expected to grow up to $1.05 B / year by 2017. A license for manufacturing and sales of the product is expected to attract the interest of big industry players, including such as Roche Diagnostics, Abbot Diagnostics, Ortho/Life Scan, Bayer/Simens, Beckman Coulter, Dade Behring/ Siemens.
CONTACTS / Moscow, +7 (903) 730 86 41 [email protected] +7 (916) 641 54 40 [email protected]
29 RECEPTOR, SPC
A NEW GENERATION BIOMATERIALS FOR BONE RECONSTRUCTIVE SURGERY
COMPETITIVE ADVANTAGES / High efficiency, reasonable cost of goods sold, the lack of negative side effects, convenience for the surgeon and guarantee the desired result in the recipient provide a dominant competitive
MEDICAL PRODUCTS & EQUIPMENT, HEALTHCARE IT HEALTHCARE MEDICAL PRODUCTS & EQUIPMENT, advantage of our products.
ESSENCE OF INNOVATION / Manufacturing technology of bone biomaterials new generation with a given osteogenic potential, providing reception of standardized matrices and a wide variety of osteoinductive fillers to increase the quality and speed of regeneration. TEAM / MARKET POTENTIAL / • Fadeev R., PhD - Researcher; According to Rosstat, the annual • Akatov V., prof. - Science Advisor; demand for materials for traumatology / • Fadeeva I., PhD - Researcher; orthopedics is nearly 20 million. Sets and • Sklyanchuk E., prof. - Science Advisor; the demand for them is growing. Due to • Lekishvili M., prof. - Science Advisor; severe competitive advantages the market • Khaustov S., PhD - Project manager. potential of our products in this segment of the market is enormous.
CONTACTS / Pushchino, Moscow region +7 (926) 957 43 77 [email protected]
30 LUMINESCENCE DIAGNOSTICS INSTRUMENTS, LLC
THE NOVEL TOOLS FOR RAPID NEAR PATIENT DIAGNOSTIC OF INFECTIOUS DISEASES
COMPETITIVE ADVANTAGES / Systems provide high precision quantitative diagnostics of infectious diseases at the point of care. Desktop, portable and mobile versions of diagnostic devices are developing for small clinics and privat users. IT HEALTHCARE MEDICAL PRODUCTS & EQUIPMENT,
ESSENCE OF INNOVATION / Application of electrochemical luminescence excitation, using cathodic TEAM / electroсhemiluminiscence, provides high • Kiselev O - Scientific Director, RAS sensitivity and accuracy of diagnosis, as Academician; well as the production of compact and • Korpela T - Research Manager; low-cost systems. • Elokhin V. - Manufacturing Director; • Chistyakov A. - Director General; MARKET POTENTIAL / • Laaksonen T. - Consultant for High sensitivity of diagnosis, ease of use, manufacturing and commercialization small dimensions and low cost of systems in EU. meet the needs of clinics and health centers of small settlements in RF, Police, Defence Ministery, Immigration Service of RF, small clinics and private users in EU.
CONTACTS / Saint-Petersburg [email protected]
31 BIOTECHNOLOGY, LLC
NEW SURGICAL MATERIAL – ADHESIVE BARRIER
COMPETITIVE ADVANTAGES / It surpasses analogues in three times for the effective prevention of adhesions. Indicators biocompatibility, hemocompatibility, strength and flexibility are better than that of analogues.
MEDICAL PRODUCTS & EQUIPMENT, HEALTHCARE IT HEALTHCARE MEDICAL PRODUCTS & EQUIPMENT, ESSENCE OF INNOVATION / The formation of adhesions is a common postoperative complication faced by more than 90% of patients. The new adhesion preventing material has been developed which is a biodegradable material biocompatible polymer comprising pharmaceuticals in its structure.
MARKET POTENTIAL / TEAM / The product has the potential to occupy • Kudryavtseva Y., PhD - Head of the a significant proportion of the market project; has a number of awards at (20-30%). The market is rapidly growing. competitions, including international; According to forecasts, the volume of the • Galeev A., Ph.D - a specialist in global market in 2018 will be about $ 3 commercialization; has successful billion. experience in the brining his company to the foreign market; • Bashkireva A. - a specialist in clinical trials; conducted 12 clinical trials involving foreign pharmaceutical companies.
CONTACTS / Kemerovo, Kemerovskaya region +7 (3842) 64 42 38 [email protected];
32 PRIMEBIOMED, LLC
CHITINASE-LIKE PROTEINS-BASED TEST SYSTEM FOR THE EARLY DIAGNOSTICS OF CANCER
COMPETITIVE ADVANTAGES / The project will develop a system for simultaneous measurement of concentrations of chitinase-like proteins (YKL-40, YKL-39 and SI-CLP) in the circulation. In order for this process to take no more than 90 minutes, the IT HEALTHCARE MEDICAL PRODUCTS & EQUIPMENT, quickest method is developed on the basis of ELISA, which will minimize the cost of clinical laboratory tests and speed up the diagnostic process.
ESSENCE OF INNOVATION / Multiplex diagnostic test based on the TEAM / analysis of 3 chitinase-like proteins YKL- • Grachev A., PhD - General Director; 39, YKL-40 and SI-CLP will be developed. • Kzhyshkowska J. PhD, Professor - This test will allow early diagnostics and Head of R&D; prognosis analysis of gliomas, colorectal, • Kovaleva O., PhD - Researcher. ovarian and prostate cancer. Developed diagnostic test will allow rapid inexpensive and highly sensitive diagnostics of tumours on early stages.
MARKET POTENTIAL / World market (Europe and USA) - 470000 tests, 9 mln USD. Russian market - 115000 tests, 80 mln. Roubles.
CONTACTS / Moscow +7 (499) 645-50-45 [email protected] www.primebiomed.ru
33 LABORATOTY OF THE INNOVATIONS, LLC
DEVICE AND TECHNOLOGY FOR ON LINE, IN VIVO BLOOD ANALYSIS
COMPETITIVE ADVANTAGES / The implementation of the project will create a framework for the development of methods, devices, medical technologies of on line, in vivo diagnostics, first of all, would create a basis for effective
MEDICAL PRODUCTS & EQUIPMENT, HEALTHCARE IT HEALTHCARE MEDICAL PRODUCTS & EQUIPMENT, diagnostics of children (without injuries, without pain, emotional stress, etc.). At present, the diagnostics based on the analysis of blood samples (IVD) is a bad one for patients, and unacceptable for children.
ESSENCE OF INNOVATION / Development of the method, devices, and medical technologies for capillary spectrometric analysis of blood samples in real time. TEAM / • Baranov V. - CEO; MARKET POTENTIAL / • Tveritinov A. - Head of Software Оver USD 2.0 billion. Department; • Baranov D. - Developer; • Prokhorov A. - Developer; • Baranov V. - Researcher; • Volkov V. - Design Engineer.
CONTACTS / Moscow Zelenograd +7 (925) 155 09 00 bww_54@ mail.ru
34 SKOLKOVO GRANT
EUROPEAN CENTER OF DEVELOPMENT FOR INNOVATIONS, LLC
MOBILE SYSTEMS ELOC FOR MULTI-PARAMETER INDIVIDUAL EXPRESS IMMUNODIAGNOSTICS
COMPETITIVE ADVANTAGES / TEAM / Multiparameter diagnostics (250 tests). • Vasilets L., MD- Director Small sample volume required of Science, the ideologist of the project; (a drop of blood). • Strizhkina A. - General Director; Low cost (less than 16 rubles). • Paradis S. - Director of Development;
Speed of measurement. • Surkov E. - Design Engineer. IT HEALTHCARE MEDICAL PRODUCTS & EQUIPMENT, «Pocket» format. Easy to use. Scalable technology platform.
ESSENCE OF INNOVATION / The development of immunodiagnostic biosensors for an individual to analyze multiple health factors, based on the «Electronic Lab on a Chip (eLOC)» technology platform.
MARKET POTENTIAL / Potential market growth for biosensors (data from Bio-Insite): in 2015 - $12.0 billion, in 2018 - $16.2 billion.
CONTACTS / Moscow +7 (916 ) 801 08 01 [email protected]
35 SKOLKOVO GRANT
BIOSTEN, LLС
BIORESORBABLE ENDOVASCULAR IMPLANTS
COMPETITIVE ADVANTAGES / We developed the technology that enables manufacturing of bioresorbable stents from composite materials to ensure the control over the process of bioresorbtion and to achieve mechanical properties that make it possible for bioresorbable stents
MEDICAL PRODUCTS & EQUIPMENT, HEALTHCARE IT HEALTHCARE MEDICAL PRODUCTS & EQUIPMENT, to acutely perform similarly to metal stents during clinical procedures.
ESSENCE OF INNOVATION / We manufacture stent prototypes from compositions of chemically produced TEAM / and biosynthesized polymers. It helps • Popov M., Ph.D - CEO; to streamline the design of stents and • Manzenyuk O., Ph.D - Project Leader; increase their mechanical stability • Drugov A. - Consultant, Technology compared to existing bioresorbable Transfer; stents. • Solovyov N., Dr. of Technical Sciences - Head of Laboratory of Laser Discharge, MARKET POTENTIAL / Institute for Problems in Mechanics RAS Global Coronary Stents Market is • Kapustin D. - Ph.D. in Technical expected to reach $10.6 billion by 2016 Sciences, Head of research group, at a CAGR of 8.3% according to BCC Laboratory of Polymers for Biology, Research. Institute of Bioorganic Chemictry RAS; • Lukyanov E. - Mentor.
CONTACTS / Moscow +7 (495) 787 37 34 [email protected] [email protected]
36 SKOLKOVO GRANT
ALPHA BIOTECH, LLC
DENTAL IMPLANT COATING THAT CAN STIMULATE OSTEOGENESIS AND HAS AN ADDRESSED EFFECT ON REGENERATIVE PROCESSES IN PERI-IMPLANT TISSUES
COMPETITIVE ADVANTAGES / The future product is currently the only biocompatible dental implant, not only able to stimulate osteogenesis, but also having antibacterial properties. IT HEALTHCARE MEDICAL PRODUCTS & EQUIPMENT,
ESSENCE OF INNOVATION / Using our experience in the development of organic hemostatic substances, we create a new surface of the dental implant with an organic coating. The new surface is an innovative organic coating of the implant, which has lots of advantages to TEAM / now produced ones. • Fromovich O. - founder Alpha Biotech, implantology held about 40 thousand MARKET POTENTIAL / implantology operations; $10 billion (World), • Freeman J. - surgeon implantologist, $300 million (Russia). author of numerous courses and Research implantology, chief physician of the clinic “The German Dental Center“; • Zabursky P. - MBA in Finance, General Director; • Kiselev S. - author of 2 patents of the Russian Federation, best innovative mendezher 2006.
CONTACTS / Moscow Abiotex.ru [email protected]
37 SCIENTIFIC AND RESEARCH INNOVATIVE DEVELOPMENTS OF MEDICAL DEVICES (NIIRM), LLC
COMBINED LYMPH AND BLOOD DETOXIFICATION APPARATUS
COMPETITIVE ADVANTAGES / Building up of types of extracorporeal procedures. Product’s similarity with analogous devices – blood detoxification, difference – method of combined or separate lymph
MEDICAL PRODUCTS & EQUIPMENT, HEALTHCARE IT HEALTHCARE MEDICAL PRODUCTS & EQUIPMENT, and blood purification. Increase of treatment efficacy, reduction of mortality.
ESSENCE OF INNOVATION / The novelty of the project as compared to Russian and world products consists of the development of methodologies and mechanisms for lymph detoxification or combined lymph and blood detoxification based on the new medical technology and hardware implementation.
MARKET POTENTIAL / Medical devices market. Segment: Health Care (efferent therapy). Geography markets around the world. World market – over $ 6.2 billion, Russia – TEAM / over $ 1.0 billion. • Glukhov V. - CEO; • Mashkin V. - Technical Director; • Karandin V. - Director, Medical technology; • Glukhov M. - Commercial Director; • Danilin A. - Scientific Consultant.
CONTACTS / Istra, Moscow region +7 (903) 712 22 97 [email protected]
38 AVKOR, LLC
STEREOSCOPIC 3D TECHNOLOGY FOR TELEMEDICINE
COMPETITIVE ADVANTAGES / We have a full range of 3D technolgies: from software to own 3D monitors.
ESSENCE OF INNOVATION / We have a full range of 3D technolgies: from software to own 3D monitors. MEDICAL PRODUCTS & EQUIPMENT, HEALTHCARE IT HEALTHCARE MEDICAL PRODUCTS & EQUIPMENT, MARKET POTENTIAL / The main target market - telemedicine services is estimated at only US $ 12 billion , of which not less than 25 % require a stereo information.
TEAM / • Invalev A. - Project Manager, experience in the aerospace Energy Corporation and Mentor Graphics Corp (USA); • Leksunov O. - Head of Petrozavodsk branch of IRTC.
CONTACTS / Korolev, Moscow region +7 (495) 502 82 01 [email protected] www.stereo-pixel.ru
39 ФУНКЦИОНАЛ f общество с ограниченной ответственностью
NPO FUNCTIONAL, LLC
INSTRUMENT AND METHODS FOR DIAGNOSIS AND INSTRUMENTAL CONTROL OF DIABETES AND QUANTITATIVE ASSESSMENT OF THE EFFECTIVENESS OF THERAPEUTIC INTERVENTIONS
COMPETITIVE ADVANTAGES / Unique opportunities for diagnosis of many pathological and normal conditions of the body that provide information about
MEDICAL PRODUCTS & EQUIPMENT, HEALTHCARE IT HEALTHCARE MEDICAL PRODUCTS & EQUIPMENT, the patient’s condition, which cannot be obtained by other known methods; rapid analysis; efficiency of evaluation of dynamics of pathology development; In Vitro. TEAM / • Rybalchenko G. - General Director; ESSENCE OF INNOVATION / • Zaritskii A. - Head of biophysical research; The developed device registers the • Proninin V. - Head medical research; process of saturation of blood sample • Tatarinov A. - Commercial Director; with oxygen, sensitive to changes in the • Kirichenko A. - Deputy head of biophysical energy of body cells even at early stages research; of formation of diabetes. The analysis of • Vorontsov Y. - Consultant, the characteristics of the recorded curve Medical research. gives an indication of the qualitative and quantitative shifts in cellular energy transfer and, consequently, about the presence and severity of diabetes and the dynamics of its development.
MARKET POTENTIAL / At least one of our devices shall be in each hospital and outpatient facility. Only in Russia it is necessary to have more than 20 thousand devices. In the world according to conservative estimates only for the implementation of measures for the diagnosis of diabetes annually, more than 250 million blood tests shall be carried out with our devices.
CONTACTS / Moscow +7 (910) 463 69 54 [email protected]
40 MEDIATOMA, LLC
HIGH-TECH SURGICAL INSTRUMENTATION FOR BALLOON KYPHOPLASTY
COMPETITIVE ADVANTAGES / The proposed for production innovative medical product is superior to foreign counterparts due to the controllable electromagnetic hydroimpulsive balloon kyphoplasty with controlled vibration frequency and impact force on the IT HEALTHCARE MEDICAL PRODUCTS & EQUIPMENT, bone tissue; a protective membrane; production technology that ensures the products’ price 2-3 times lower than that of competitors.
ESSENCE OF INNOVATION / TEAM / The essence of innovation lies in the ability • Toma A. - General Director; to safely restore the height of the injured • Dorokhov D. - Financial Director; vertebral body through the use of controlled • Altukhov P. - Chief economist; balloon kyphoplasty, the application of • Yelkin V. - Head of the scientific ultrasonic sealer, electromagnetic valve to laboratory; create hydroimpulse to reduce the load on • Toma I. - Head of international relations, the balloon and giving it the shock property. innovation and intellectual property department. MARKET POTENTIAL / Assessing the market of the offered high- tech tools, it can be noted that in the country (the Russian Federation) and the near abroad there are over 30,000 sets for operations per year amounting to more than RUB 1,200 million. In the world there are more than 700,000 sets for operations per year amounting to more than RUB 28 billio.
CONTACTS / Saratov Moscow, Skolkovo +7 (926) 183 21 58 [email protected] www.mediatoma.ru
41 SKOLKOVO GRANT
INNOVATIVE TECHNOLOGIES, LLC (INNOVATECH, LLC)
HARDWARE AND SOFTWARE COMPLEX BASED ON BRAIN- COMPUTER INTERFACES (BCI) TO CONTROL PROSTHETIC DEVICES FOR THE REHABILITATION OF POST-STROKE PATIENTS
COMPETITIVE ADVANTAGES / Hybrid BCI training device of the new generation, which allows using the mental effort of the patient to train not only
MEDICAL PRODUCTS & EQUIPMENT, HEALTHCARE IT HEALTHCARE MEDICAL PRODUCTS & EQUIPMENT, massive movements of hands, but also fine finger coordination, which significantly improves quality and accelerates rehabilitation of poststroke patients.
ESSENCE OF INNOVATION / The innovation lies in the hybridization simultaneously of two BCI technologies: working both on the EEG changes at the visualization of the general movement, and the specific reactions of the EEG, reflecting the intention to the movements of individual fingers. TEAM / MARKET POTENTIAL / • Kaplan A. - Scientific Director, author Neurotraining devices reduce the time of patents, neurophysiologist, Ph.D. and improve the quality of rehabilitation professor; of poststroke patients. Annually in • Basyul I. - CEO, neurophysiologist; Russia one registers up to 500 thousand • Borisov S. - Head of Data Analysis new stroke patients, whose standard group. rehabilitation costs up to RUB 60 billion. • Lobusov E., PhD - Neurophysiologist, It is expected that neurotraining devices medical support; will be purchased by medical institutions • Ganin I., Ph.D - Neurophysiologist, and individuals. group medical and biological testing.
CONTACTS / Moscow [email protected]
42 GENEXT, LLC
PRENATAL TESTS. TEST SYSTEM FOR THE EARLY NONINVASIVE PRENATAL DIAGNOSIS OF ANEUPLOIDY
COMPETITIVE ADVANTAGES / The test system for non-invasive Diagnostics - blood pregnant early - from 10 weeks of pregnancy, It focused on PCR - available to perform any practical
Laboratories. IT HEALTHCARE MEDICAL PRODUCTS & EQUIPMENT,
ESSENCE OF INNOVATION / Unique innovative algorithm ratio differentially methylated different regions of the chromosomes of the fetus and mother. TEAM / • Toropovsky A. - CEO; MARKET POTENTIAL / • Nikitin A. - Senior researcher; 1 billion US dollars. • Zhmyrko E. - Head of laboratory; • Victorov D. - Researcher: • Zaikin A. - Business Director; • Belyakov A. - Commercial Director.
CONTACTS / Ulyanovsk region, Industrial zone « Zavolzhe» +7 (917) 621 44 44 +7 (927) 809 20 45 [email protected], [email protected]
43 CENTER OF ADVANCED MEDICAL RESEARCH BERIKON, LLC
HARDWARE-SOFTWARE COMPLEX FOR DIAGNOSTICS ASTHMA IN CHILDREN
COMPETITIVE ADVANTAGES / TEAM / Non-invasive and painless diagnosis • Berezhanskiy P.,PhD, - pediatrician, from birth (all known diagnostic methods researcher, the author of the project; are applicable to children older than 5 • Koninskiy A. - co-author of the project; years old), high specificity and sensitivity, • Mizernickiy Yr.L., PhD, Prof, - Chief
MEDICAL PRODUCTS & EQUIPMENT, HEALTHCARE IT HEALTHCARE MEDICAL PRODUCTS & EQUIPMENT, portability and ease of use, low production pediatric pulmonologist Ministry of health cost. of Russia, Director of Children’s scientific- practical pulmonale-environmental center; ESSENCE OF INNOVATION / • Melnikova Ir.M.,PhD, Prof, - Consultant A compact hardware and software system programme global strategy for asthma. has been created.It allows the new innovative level to perform early diagnosis of allergic diseases at the stage of the absence of clinical manifestations to reduce the chronicity and disability at an early age.
MARKET POTENTIAL / Statistics from WHO Asthma: 13% of adults, 11.6% of children,250,000 deaths from asthma per year, by 2020 the number of asthma sufferers will have increased to 28% (nearly 3rd person in the world).Market size: $47.3 billion (42.2 % - Canada/USA, the EU-32,5%). Upmarket : 2013 - 7%, 2014 - 5.8%.
CONTACTS / Odintsovo, Moscow region +7 (915) 145 50 13 [email protected]
44 DATA MATRIX, LLC
MATRIX CLOUD — CLOUD-BASED APPLICATION FOR DRUG DEVELOPMENT MANAGEMENT
COMPETITIVE ADVANTAGES / Compliance with local regulations, requirements and features of the Russian market; computarization of all processes of clinical trials; accurate standardization of data; the data array creation of specific IT HEALTHCARE MEDICAL PRODUCTS & EQUIPMENT, drug during the entire period of its development.
ESSENCE OF INNOVATION / We develop the unique automatization system for processing clinical data in Russia. New functionality development helps to optimize the clinical trials process and reduce the cost of software and allows TEAM / small companies to conduct clinical trials • Leus K. - CEO; according to GCP. • Kuzmin A. - Head of Software Development Department; MARKET POTENTIAL / • Prutsky V. - Project Adviser; There are no analogue solutions on the • Shakhova A. - Business Development Russion market. Date MATRIX takes the Director. leading position on the market, providing high quality software and related services which meets the requirements of customers.
CONTACTS / St. Petersburg +7 (812) 449 8633 Ext : 2027 +7 (911) 772 9563 [email protected]
45 R&D INTERCELL, LLC
TECHNOLOGY FOR NON-INVASIVE MEASUREMENT OF BLOOD SUGAR
COMPETITIVE ADVANTAGES / Non-invasive glucometer, proposed for development, will meet the needs of consumers for the accuracy parameter, and will also have a number of advantages: absence of pain effect;
MEDICAL PRODUCTS & EQUIPMENT, HEALTHCARE IT HEALTHCARE MEDICAL PRODUCTS & EQUIPMENT, no operating costs; the ability to obtain data in monitoring mode.
ESSENCE OF INNOVATION / The project aims to develop a fundamentally new product (market blood glucometers, which is estimated at innovation) - a non-invasive glucometer 10 billion dollars a year. In particular, the for bloodless measurement of blood sugar market for test strips for invasive blood and metabolic rate of the local area glucometers in the USA only reaches USD of a living human tissue.A fundamentally 3.5 billion a year. new method of bloodless blood sugar measurement is based on determining TEAM / the thermal effect of tissue metabolism • Musin R. - Director; by high-precision non-invasive • Antsiperov V. - Programmer; measurement of tissue pressure - • Abbott W. - Manager; the osmotic pressure of the intercellular • Yanovich A. - Electronics Engineer; substance of the epidermis. A new • Shvetsov A. - Physiologist; method for measuring the thermal • Stromilov A. - Commercial Director. effect of the metabolism of living tissue allows to carry out high-precision non- invasive measurement of a number of physiological and biochemical parameters, characterizing the metabolism of the local area of a living tissue, in particular, blood sugar level.
MARKET POTENTIAL / Potential consumers of the project product are the patients suffering from diabetes, who in the cource of insulin therapy shall control the blood sugar level throughout the day with a view to the timely injection of the required dose of insulin. The total number of patients with diabetes, according to the International Diabetes Federation (IDF) in 2013 reached a record level of 382 million, of which about 7-8 million are in Russia and about 26 million (8.3% of population) are in the United States. The global market volume CONTACTS / of noninvasive blood glucose meters Moscow can be assessed as comparable to the +7 (985) 226 98 70 volume of the world market of invasive [email protected]
46 INTRO-MICRO, LLC
INDIVIDUAL GAS-ANALYZER BASED ON COLLISIONAL ELECTRON SPECTROSCOPY (CES) FOR A CONTINUOUS NON-INVASIVE MEDICAL MONITORING
COMPETITIVE ADVANTAGES / Our hand-held volatile biomarker molecules detector is based on Collisional Electron Spectroscopy (CES) method, which is protected by our patents US IT HEALTHCARE MEDICAL PRODUCTS & EQUIPMENT, 7,309,992, Japan 4408810, China ZL200380106502.2, Germany, France and UK - EP 1557667, Russia 2217739. TEAM / ESSENCE OF INNOVATION / • A. Tsyganov, Ph.D (physics) - CEO, Breathing provides volatile bio-marker founder, device concept and electronics molecules of early signs of lung and development; mammary cancer, tuberculosis, COPD, • N. Luneva, M.D., professor at St.- asthma, diabetes, Crohn disease, Petersburg State University - Medical ulcerative colitis, etc. We offer hand-held Research; CES-analyzer for every-day non-invasive • G. Panasyuk, Ph.D. (physics) - Software monitoring and diagnostics. Development; • D. Zashcherinskiy, M.S. (economics), serial MARKET POTENTIAL / entrepreneur - Business Development; Individual mobile health devices • M. Budilov, attorney at law - Lawyer (m-Health) are the emerging market. Non- Advisor. invasive, easy-to-use in every-day life, pocket-size analyzer of volatile biomarkers is absent at the market still. The market potential might be as high as 1 Billion users (with retail price of < $1K).
CONTACTS / St. Petersburg +7 (812 )925 25 34 [email protected]
47 SKOLKOVO GRANT
CRYOTON, LLC
EARLY DETECTION OF VIOLATIONS OF THE ELECTROPHYSIOLOGICAL PROPERTIES OF THE MYOCARDIUM ON THE BASIS OF MAGNETOCARDIOGRAPHY
COMPETITIVE ADVANTAGES / The possibility to work with magnetocadiographs at conventional clinical conditions without additional magnetic shielding. MCG-systems are
MEDICAL PRODUCTS & EQUIPMENT, HEALTHCARE IT HEALTHCARE MEDICAL PRODUCTS & EQUIPMENT, easi to use, , they provide high quality diagnostic results, a lower cost than competitive counterparts.
ESSENCE OF INNOVATION / Innovation of the project goes from the creation of an original, high-end hardware and software solutions for the visualization of electrical processes in the heart, allowing them to obtain significant results in the application of Heart condition’s diagnosis.
MARKET POTENTIAL / It is necessary to install of about 5000-6000 magnetocardiograph, such as «MAG-SCAN-09». At a cost of about $ 200,000, in the world TEAM / the potential market size is one billion US • Y. Maslennikov, Ph.D - Project Manager; dollars. • V.Krymov,Ph.D - Technical Director; • M. Primin, Ph.D - Leading Mathematician; • V. Slobodchikov - Leading Engineer; • V. Khanin - Leading Engineer; • A. Okunev - Leading Engineer.
CONTACTS / Moscow +7 (962) 923 47 62 +7 (495) 621 73 22 [email protected]
48 MEDEL, LLC
EARLY DETECTION OF VIOLATIONS OF THE ELECTROPHYSIOLOGICAL TANTALIC ELECTRET STIMULATORS FOR OSTEOREPARATION (ESO) PROPERTIES OF THE MYOCARDIUM ON THE BASIS OF MAGNETOCARDIOGRAPHY COMPETITIVE ADVANTAGES / Minimally invasive and organ-preserving method in comparison to endoprosthesis treatment. Significant reduction in cost of treatment. Reduction of treatment time and no need for rehabilitation. No risks and contradictions. MEDICAL PRODUCTS & EQUIPMENT, HEALTHCARE IT HEALTHCARE MEDICAL PRODUCTS & EQUIPMENT, ESSENCE OF INNOVATION / Problem of treatment of joint osteoarthritis is solved using electrical stimulation of osteoreparation processes by quasi- stationary electric field of electrets in vicinity of necrosis.
MARKET POTENTIAL / TEAM / Market volume of treatment methods for • Morgunov M., PhD - General Director; osteoarthritis in Russia is ~ $70 • Khomutov V., Ph.D.- Deputy General mln., growth rate of it is ~ 2.5%. Director for medical issues; However, market potential is much • Orlov V.,Dr.- Consultant, technological larger (~ $300 mln.). Market potential issues, Honored metallurgist of the RF. of treatment methods for osteoarthritis in world is > $20 bln.
CONTACTS / Saint-Petersburg +7 (921) 903 72 56 +7 (812) 384 43 01 +7 (908) 209 90 04 [email protected] [email protected]
49 HEALTH MONITORING, LLC
“BRIGHT HELMET” — THERAPY SYSTEM
COMPETITIVE ADVANTAGES / Non invasive technology, portability, increase depth of transcranial penetration, high potential of optical topography of the cerebral cortex to analyze the cognitive activity.
MEDICAL PRODUCTS & EQUIPMENT, HEALTHCARE IT HEALTHCARE MEDICAL PRODUCTS & EQUIPMENT, ESSENCE OF INNOVATION / Non-invasive technology therapy for patients after Acute cerebral circulation problems and (or) cranial trauma. The technology is based on use of pulsed infrared light irradiation and includes unique cooling technology of modules emitters on high-brightness LEDs, remote control units adаpted for home exploitation.
MARKET POTENTIAL / TEAM / World - 3.4 billion USD; • V. Monich, Dr., Professor, Head RF -2.9 billion rubles. of the Volga branch, Academy of Medical and Technical Sciences. Head of Department Medical Physics and Informatics NizhGMA; • V. Samofalov, Ph.D. - Director of Nizhny Novgorod branch of Intel; • R. Alakaev., Ph.D. - an economist. Experience in managing research and commercial projects as general director of the Foundation «Medtelecom» (2005-2014); • V. Grigorieva, doctor of the highest qualification category, MD, Professor - Head of Department of Neurology, Neurosurgery and Medical genetics NizhGMA.
CONTACTS / N.Novgorod +7 (831) 465 50 51 [email protected] [email protected]
50 MOTORICA, LLC
EXPRESS PROSTHETICS
COMPETITIVE ADVANTAGES / Prosthetics for the unique trauma of the upper limbs Low cost Available in all regions of Russia The unique VR training system for the myoelectric prosthesis. MEDICAL PRODUCTS & EQUIPMENT, HEALTHCARE IT HEALTHCARE MEDICAL PRODUCTS & EQUIPMENT, ESSENCE OF INNOVATION / Reducing the cost of the product through the use of 3D printing, personal approach the design of the prosthesis and Installation service, unique learning TEAM / system based on virtual reality. • I. Chekh - CEO, Ideological and technological project inspirer. Master’s MARKET POTENTIAL / degree in the Mechatronics. Extensive In 2013, 5,405 items of upper limbs experience in developing mechatronic prostheses were dispensed for a total devices for different purposes; amount of 176.7 mln. • V. Khlebnikov - CMO, Marketing rubles, which is 6.8% from the total Specialist and work with partners. volume of money intended for providing Co-founder of several successful rehabilitation equipment. companies, including international: The capacity of the upper limb prostheses can-touch.ru, rizzoma.com, BetCourt. market is 1.7 bln. rubles in monetary terms.
CONTACTS / Moscow +7 (911) 241 03 09 [email protected]
51 FM DIAGNOSTICS, LLC
MICROTEST
COMPETITIVE ADVANTAGES / Non-invasive diagnostics technique; express-analysis of vascular tone; ease of handling, safety and low cost of the diagnostics complex compared to peers.
ESSENCE OF INNOVATION /
MEDICAL PRODUCTS & EQUIPMENT, HEALTHCARE IT HEALTHCARE MEDICAL PRODUCTS & EQUIPMENT, Technique of diagnostics of endothelial dysfunction is based on wavelet-analysis of high-resolution skin thermometry. Hardware and software system of endothelial dysfunction diagnostics. TEAM / MARKET POTENTIAL / • Smirnova E.- Ph.D., head of the Cardiologists and endocrinologists — PGMU the department; 4’000 devices; general practitioners — • Podtaev S. - Head: Dr., Director 17’000 devices; health spa and resort R & D; institutions. • Frick P. - Prof., Head laboratory ICMM UB RAS; • Stepanov R. - Dr., Director STC “FM diagnostics”; • Kleshchev D. - Higher School of Economics.
CONTACTS / Perm, Rerm Region [email protected]; www.fm-diagnostics.com
52 HEALTH MODELLING TECHNOLOGY, LLC
“ECLONE” - ONLINE GAMIFICATION SERVICE FOR SMARTPHONE- AND TABLET-BASED EMR VISUALIZATION
COMPETITIVE ADVANTAGES / Provides full reflection of health parameters on the virtual body model. Integrated with official systems of storing medical data. Gives access to information about medical services and products allowing for their IT HEALTHCARE MEDICAL PRODUCTS & EQUIPMENT, comparison in comfortable and game- based form and so assisting to informed user choise.
ESSENCE OF INNOVATION / TEAM / The project develops an automated expert • Simakov O. - CEO; system for analytical processing of the • Kuznetsov P. - Healthcare Management, health parameters of an individual. Results Healthcare IT and Healthcare Economics are provided in the user-friendly graphical Specialist; descriptive way in a format easily • Adamov V. - Specialist understood by individuals without medical in Enterpreneurship Support; education. • Komissarova A. - Vice-Director of the Russian Marketing Association; MARKET POTENTIAL / • Gant A. - ISO 215 Technical Committee Primary target group for our system is member, medical IT (Canada). age 12-35 years. Moscow city has 3.9 mln. users within this age group and the volume of internal market is estimated to 16 mlns. (counting only cities with population over 1mln.) The total volume of the world market exceeds 2billions persons.
CONTACTS / Moscow +7 (903) 795 97 70 [email protected] +7 (499) 606 03 02 [email protected]
53 MEDICAL TECHNOLOGIES OF BELGOROD STATE UNIVERSITY, LLC
PORT SYSTEM WITH PTFE COATING OF AMORPHOUS CARBON PROLONGED INFUSION-TRANSFUSION THERAPY
COMPETITIVE ADVANTAGES / TEAM / Low price in comparison with foreign • Naberezhnev Y., Ph.D - Director, analogues. Author of the project; The quality of the product meets • Konoplya A. - Commercial Director; international standards • Kolpakov A., Ph.D - Monitoring and
MEDICAL PRODUCTS & EQUIPMENT, HEALTHCARE IT HEALTHCARE MEDICAL PRODUCTS & EQUIPMENT, Duration of use exceeds foreign development process. analogues.
ESSENCE OF INNOVATION / • Amorphous carbon has a bactericidal action, which reduces the risk of infectious inflammation; • Amorphous carbon creates a perfectly smooth surface, which prevents the formation of blood clots and drug plugs; • The port can be used without reinstalling up to 5 years.
MARKET POTENTIAL / Target audience: Oncologic dispensaries, hospitals, centers. Patients suffering from oncological diseases. Departments of resuscitation and intensive therapy. The market size is EUR 47 million.
CONTACTS / Belgorod +7 (910) 323 12 47 [email protected] www.npp-medtech.ru
54 SIBERIAN WATER TECHNOLOGIES, LLC
AUTONOMOUS TREATMENT AND RECYCLING OF WASTEWATER ON A WATER CONSUMPTION SITE
COMPETITIVE ADVANTAGES / Separate processing of wastes of different origination. The high moisture capacity of the complex treatment facilities. The use of automated processes for the purify-cation and recycling of components IT HEALTHCARE MEDICAL PRODUCTS & EQUIPMENT, of flow and follow (according to sanitary standards).
ESSENCE OF INNOVATION / Solid and liquid fractions are treated separately. Solid fraction comes to composter. Liquid fraction flows into Microbiological Fuel Cell or on the device TEAM / for physical-chemical treatment and • Zhukov B.- Executive with experience constructed wetland. Water treatment of over 20 years, the company facilities are placed in insulated room - “Eco-house”, Senior Scientist, Institute heat accumulator. of Inorganic Chemistry, associate professor of Novosibirsk State Technical MARKET POTENTIAL / University; The target market is energy and resource- • Uvarov N. - Prof., Head of R&D, Dr.Sc. saving treatment of domestic wastewater, in Chemistry. Prof., Leading Researcher estimated as $12-15B. The Russian at Inst. of Solid State &Mechanic market of wastewater treatment will grow Chemistry of Sib. Branch of RAS; by $20-30M per year driven by tougher • Zhukov A. - Commercial Director. penalties and administrative The main competitors are septic tanks producers or two - three-chambered anaerobic aerobic bioreactors.
CONTACTS / Novosibirsk +7 (913) 919 35 57 [email protected]
55
SIMBIOTECH, LLC
TECHNOLOGY FOR PRODUCTION OF “BIOLOGICAL MODELS” FOR PRACTICING GENERAL SURGICAL AND ENDOSCOPIC MANIPULATION
COMPETITIVE ADVANTAGES / Multifunctional surgical simulator Low cost simulator and biomodels No domestic analogues.
MEDICAL PRODUCTS & EQUIPMENT, HEALTHCARE IT HEALTHCARE MEDICAL PRODUCTS & EQUIPMENT, ESSENCE OF INNOVATION / Development of technology for production of highly realistic models of surgical pathology of biological material of animal origin. Development of a universal surgical simulator of a modular type with interchangeable biomodels of surgical pathology,corresponding to the topics of study. TEAM / • Rebrikov D.; MARKET POTENTIAL / • Ivanov А.; The products are of interest to medical • Lutsenko N.; and veterinary educational institutions, • Petrova K.; specialized training centers, medical • Yakusheva Y.; companies to demonstrate the capabilities • Yevteyev D. of surgical equipment. Every year in Russia there are more than 100 practical trainings, at which our training device and «biomodels» can be used. In addition, «biomodels» can be used in the medical industry in the development and testing of tools, equipment and consumables.
CONTACTS / Moscow +7 (903) 199 00 89 [email protected] [email protected] [email protected]
56 ALLCARDIO, LLC
EPICARDIAL WIRELESS PACING SYSTEM. ACTUALIZATION AND MODERNIZATION — THE WAY TO THE MARKET PENETRATION AND EXPANSION
COMPETITIVE ADVANTAGES / Pacemaker is wireless, miniature, implanted epicardial. Developing an algorithm of wireless data exchange will allow to work on different heart chambers IT HEALTHCARE MEDICAL PRODUCTS & EQUIPMENT, two implanted epicardial pacemaker for wireless physiological pacing.
ESSENCE OF INNOVATION / There are no analogous for the epicardial wireless pacemaker in the medical society, and creation a wireless network for the data exchange between wireless devices implanted in the body is absolutely innovative idea. TEAM / • Bokeria O. - CEO, MARKET POTENTIAL / FGBI “NC MHS im.A.N. Bakuleva” Asking price for the new model Russian Ministry of Health; is 3 times lower than the average price • Kudzoeva Z. - FGBI “NC MHS im.A.N. of imported devices.Promotion of the new Bakuleva “ Russian Ministry of Health; model will be based on the clinical and • Bogin V. - Project Manager, economic benefits of the new generation President and CEO, Cromos Pharma, LLC pacemaker, as well as the lower cost. (International CRO).
CONTACTS / Moscow, +7(926) 879 22 39 Osennaya str. 23, build. 1, room 16, 121609
57 RESEARCH AND PRODUCTION ENTERPRISE “INTEGRACIA”
OPHTHALMOLOGICAL COMPLEX FOR PARAMETRICAL MONITORING OF VISUAL FUNCTIONS AND RECOVERY OF EYESIDE
COMPETITIVE ADVANTAGES / TEAM / The complex has a high degree • Strizhebok A. - General Director; of automatization, standartization • Senko I. - Senior engineer; and control of the conditions of the • Takhchidi Kh. - Corresponding Member diagnostic and therapeutic procedures of the Russian Academy of Sciences,
MEDICAL PRODUCTS & EQUIPMENT, HEALTHCARE IT HEALTHCARE MEDICAL PRODUCTS & EQUIPMENT, performed. Illustrative, documented, Professor, d.m.s.; and multiparametric presentation • Sidorenko E. - Corresponding member of results is provided. of the Academy of Medical Sciences, Professor, d.m.s.; ESSENCE OF INNOVATION / • Rozhkova G. - Professor, Doctor Medical and diagnostic ophthalmological of Biologica; complex will ensure the accuracy, reliability • Zhiltsova I., PhD - Associate Professor. and validity of the evaluation of visual functions. It will enable early detection of disorders of the visual impairments, and their efficient therapeutic correction.
MARKET POTENTIAL / The complex being developed will be used in health care and education institutions. Preventive modules of the complex can be used by private users at home.
CONTACTS / Moscow +7 (985) 766 95 41 +7 (909) 691 96 33 +7 (499) 739 56 94 12/1 Fakultetskiy lane [email protected]
58 SEMIOTIK, LLC
MICROCHIP MANUFACTURING FOR BLOOD IMMUNOGLOBULINS DETECTION
COMPETITIVE ADVANTAGES / The analysis on hundreds immunoglobulins reveals 100 pathologies by using single chip. Decrease the false- negative result percentage due to multiple versions of one antigen on the chip. High sensitivity; dynamic range is several IT HEALTHCARE MEDICAL PRODUCTS & EQUIPMENT, orders wider comparing with ELISA.
ESSENCE OF INNOVATION / The plastic chip with 500 antigens in four repeats replaces usual test systems, simplifying analysis and reducing the their cost; it allows realizing the cancer diagnosis using signatures of markers. TEAM / 500 antigens allow analyzing probe on • Bovin N. - General Director; hundreds immunoglobulins, revealing • Vlasov S. - Business development 100 pathogens. director; • Shilova N. - Senior chip specialist; MARKET POTENTIAL / • Nokel A.- General technical manager; The general capacity of potential market • Pazynina G. - Senior synthesis segments in the Russian Federation in specialist. 2015 will be 10,75 million analyses. The planned share of the Russian Federation market of microchips in 2016 is prognosed on 0,8% or 88 thousand microchips.
CONTACTS / Moscow +7 (495) 330 71 38 +7 (495) 330 61 29 [email protected] [email protected] [email protected]
59 SKOLKOVO GRANT
JOINTECHCELL, LLC
CLOSED SYSTEM OF EXPRESS EXTRACTION AND PROCESSING OF ADIPOSE-DERIVED STEM AND REGENERATIVE CELL FRACTION TO BE USED IN MEDICAL PRACTICE
COMPETITIVE ADVANTAGES / There are 4 main advantages of MiniStem technology over the similar technological solutions of the competitors: no need in NEW METHODS OF INTERNAL DISEASE TREATMENT sterile room, clinical grade of the cells, easy to use, cost-efficient.
ESSENCE OF INNOVATION / We developed the concept of innovative device where the processes of adipose tissue processing and cell fraction extraction are completely isolated from the environment. All you need is the patient, physician and MiniStem. TEAM / MARKET POTENTIAL / • Petkova M. - General Director; It is expected that MiniStem is going to be • Katz N. - Director of Science; more affordable and convenient alternative • Pustyl’nik F. - Project Manager. to the available bulky and expensive systems for processing adipose tissue, especially after cell-based technologies will be legalized.
CONTACTS / Moscow +7 (916) 130 79 36 +7 (495) 668 39 11 [email protected]
60 SKOLKOVO GRANT
PHARMA BIO, LLC
SYNTHETIC PEPTIDE DRUGS THYMODEPRESSIN: IMMUNE SUPPRESSOR AGAINST AUTOIMMUNE DISORDERS, STEMOKINE: HEMOPOIETIC & IMMUNE STIMULANT, SEDATIN: ANXIOLYTIC, STRESS-PROTECTOR, OPILONG: TREATMENT OF ALCOHOL DEPENDENCE. С12: THERAPEUTIC VACCINE AGAINST ALZHEIMER’S DISEASE
COMPETITIVE ADVANTAGES / • Superior safety profile NEW METHODS OF INTERNAL DISEASE TREATMENT • Proven high efficacy • No serious side-effects in clinical trials • Good tolerability • Convenient dosage form • Lower price compared to existing therapies • High margins.
ESSENCE OF INNOVATION / Launching and marketing of a portfolio TEAM / of five original peptide-based drugs on • Deigin V., - CEO, Doctor of Biological the Russian market, as well as further Sciences; commercialization of the portfolio on • Ivanov V., - Scientific Director, Doctor of international markets. Chemical Sciences, Academician; • Volpina O. - Head of Alzheimer’s MARKET POTENTIAL / Research, Doctor of Chemical Sciences; The volume of the Russian market in • Deigin Y. - Managing Director, MBA billions of rubles: Columbia Business School; • Autoimmune disease > 54 • Avseenko V. - Director of Business • Restoration of hematopoiesis > 32 Development, MBA ANE MSU. • Anti-stress > 410 • Anti-alcoholism > 16 The potential sale of the license for Alzheimer > 1.1 billion rubles.
CONTACTS / Moscow +7 (985) 277 06 52 [email protected]
61 SKOLKOVO GRANT
VALENTECH, LLC
NOVEL ATYPICAL ANTIPSYCHOTIC WITH UNIQUE PROFILE OF SAFETY AND EFFICACY
COMPETITIVE ADVANTAGES / Developed drug candidate will be more effective and less toxic than atipsychotic drugs currently present on market.
ESSENCE OF INNOVATION / NEW METHODS OF INTERNAL DISEASE TREATMENT The drug candidate is analogue of the most potent antipsychotic drug clozapine. Chemical modification of benzodiazepine ring was introduced to avoid formation of toxic metabolites.
MARKET POTENTIAL / The drug will be commercialized TEAM / on international market. The first • Zapolsky M. - CEO, 15+ years in market segment is patients with drug pharmaceutical business on senior resistant schizophrenia. Exit to first- positions; line antipsychotic therapy is planned • Beniashvili A. - Head of clinical on successful proof-of-concept trial development; completion (market vol $18 bn) • Morozova M. - Head of preclinical development, Head of laboratory of psychopharmacology, Mental Health Reasearch Center; • Nesteruk V. - Business development consultant.
CONTACTS / Moscow +7 (916) 089 05 52 [email protected]
62 SKOLKOVO GRANT
THERAMAB, LLC
NEW THERAPEUTIC MONOCLONAL ANTIBODY TO TREAT AUTOIMMUNE DISEASES
COMPETITIVE ADVANTAGES / Opposite to other mAbs, TAB08 is able to affect key aspects of pathogenesis via specific proliferation of T-regulatory cells, rather than tackling “consequences” of autoimmune diseases such as a blockade of TNF or IL-6. NEW METHODS OF INTERNAL DISEASE TREATMENT
ESSENCE OF INNOVATION / TAB08 is the unique drug to treating Autoimmune and Oncological diseases. This is the “first-in-class” humanized mAb of IgG4 class which mode of action is based on binding to costimulating receptor CD28 specific for human TEAM / Т-lymphocytes • Dr. D.Tyrsin - CEO; • Dr. S. Chuvpilo - Head of TheraMAB MARKET POTENTIAL / LLC Germany; TAB08 has a high market potential • Dr. A. Matskevich - CSO; to solve problems of lack • D. Nemenov, MD - Medical director; of effectiveness and frequent side effects • Y. Fedotov - Director of Drug in the existing competitive monoclonal Development. antibodies. The product has a blockbuster potential.
CONTACTS / Moscow +7 (495) 974 74 01 www.theramab.ru
63 ANGIO LAB, LLC
NANOPLASM. TECHNOLOGY FOR STIMULATION OF NEW BLOOD VESSELS’ GROWTH
COMPETITIVE ADVANTAGES / Low risk of infection – elimination of danger of infection of the patient with viral hepatitis, HIV and other infection Low cost – compare to the alternative solutions (estimated 10.000 to 300.000 NEW METHODS OF INTERNAL DISEASE TREATMENT roubles per operation) Permission of clinical use in Russia – awarded by RosZdravNadzor.
ESSENCE OF INNOVATION / TEAM / Angiogenesis stimulation in ischemic • A. Dragunov, PhD (Russia) – inventor tissues after injection of the and founder of the Company, practicing biopreparation, based on polypeptide heart surgeon and chief researcher; growth factors 5-50 kDa (approximately • A. Sheider, PhD (USA) – founder of Cure 10 nm) obtained from a patient’s own Lab (USA) and SL Oncology (Russia), blood enriched by platelet. Skolkovo resident; • S.Markov (Russia) – heart surgeon; MARKET POTENTIAL / Vita Scherbinina (Ukraine) – research According to the latest scientific data, coordinator; published “the Lancet” magazine • A. Andreev (Russia) – general manager. in August 2013, over the last 10 years the number of the people with obliterating diseases of lower limb arteries increased by almost 25% and amounts to about 200 million people.
CONTACTS / Cheboksary, Chuvash Republic +7 (800) 234 17 70 +7 (927) 849 65 34 [email protected], [email protected]
64 NEUROMAX, LLC
MEDICATION FOR THE PATHOHENETIC TREATMENT OF DIABETIC POLYNEUROPATHY (BNV-222) AND MEDICATION FOR THE NEUROPATHIC PAIN TREATMENT (AQU-005)
COMPETITIVE ADVANTAGES / BNV-222: There is no medication for pathogenetic treatment of diabetic polyneuropathy in the market. AQU-005: There is no alternative to opioid analgesics NEW METHODS OF INTERNAL DISEASE TREATMENT in the treatment of severe neuropathic pain at the moment. More then 60% of patients receive ineffective therapy with a low safety lavel.
ESSENCE OF INNOVATION / TEAM / ВNV-222: With an excess of glucosa in the • J. Moskot - General Director, Clinical blood aldose reduktase enzyme activity Study Manager; leads to metabolic abnormalities in nerve • A. Eliseev, Ph.D. - Business function. Inhibition of this ensyme is able Development, more than 17 years to reduse the progression of neuropathic experience in the venture capital industry symptoms. (Europe, USA, Russia). AQU-005- selective inhibitor of matrix metalloproteinase MMP-2, MMP-9. The action of the drug provides two parallel mechanism of neuropathic pain control in the early and late stages of its occurrence.
MARKET POTENTIAL / The volume of the main markets in 2011 was: BNV -222: $ 640 million; AQU-005: $ 6,3mlrd. Growth from 2011 to 2016 will be 7.2%; In the Russian Federation: treatment of DPN is assigned 190 thousand patients, pathogenetic therapy market is estimated at 1 billion rubles.
CONTACTS / Moscow +7 (495) 726 52 53 [email protected]
65 SANTE FARM, LLC
MULTICIDE® ORIGINAL ANTISEPTIC/DISINFECTANT
COMPETITIVE ADVANTAGES / TEAM / Broad spectrum of antibacterial, • Tets V. - General Director; antifungal, sporicidal, antiviral (against • Tets G. - Director of Science; enveloped and non-enveloped) action. • Gulo A. - Development and Possess the highest antimicrobial activity Commercialization Director; compared with any existing antiseptics. • Zaslavskaya N. - Antimicrobial Activity Penetrates microbial biofilms. Low toxic, Research. NEW METHODS OF INTERNAL DISEASE TREATMENT no irritating effect.
ESSENCE OF INNOVATION / Novel molecular entity. Nanosized molecule 1.5-2.0 nm thus possessing unique characteristics. Patents are granted in Russsia, EU, US. Additional patent protection is ongoing in other countries.
MARKET POTENTIAL / Product will be realized in antiseptics/ disinfectant market. Is registered in Russia and the manufacturing is launched in Russia (can be used for import substitution).
CONTACTS / St. Petersburg +7 (921) 908 33 94 [email protected]
66 BIOCONSTRUCTOR-S, LLC
BIOCONSTRUCTORS TECHNOLOGIES IN REGENERATIVE MEDICINE
COMPETITIVE ADVANTAGES / Modern implants for bone tissue engineering promote bone growth in vivo with 75% probability, at the best case. So, three of four patients will have successful results of osteosynthesis, only. The company has a know-how and technology of surface modification that allows NEW METHODS OF INTERNAL DISEASE TREATMENT enhancing the effectiveness of the bone growth in vivo up to 95-100%.
ESSENCE OF INNOVATION / Know-how and lab technology of artificial niches size and their distribution density designing to enhance TEAM / osteogenic properties of stromal stem • Dr. I. Khlusov - CEO. 10 years cells. Implants with surface modification of experience as Prof. of Tomsk are successfully tested in clinics. Polytechnic University and business experience at Center for Orthopaedics MARKET POTENTIAL / and Medical Materials Science (Tomsk); Tissue engineering and cell technologies • Dr. Y. Sharkeev - Head of R&D. Prof. and products are an active market, with of Institute of Strength Physics many participating companies, incl. and Material Science of Siberian Branch Johnson & Johnson Inc. / DePuy, of RAS (Tomsk); Medtronic, Smith & Nephew, Stryker, • Dr. V. Pichugin - Scientific Advisor. and Zimmer. Bone implants have 54 % Head of Department, Tomsk Polytechnic of implants market. The market is University. expected to grow 12% CAGR and will achieve 150 % ($ 100 billion) until 2018.
CONTACTS / Tomsk, Tomsk region +7 (913) 823 39 62 [email protected]
67 ELEVENTA, LLC
DRUG (OC000459) FOR PATHOGENETIC TREATMENT OF ALLERGIC DISEASES
COMPETITIVE ADVANTAGES / Reduces the frequency and severity of asthma exacerbations. Reduces the frequency of respiratory tract infections. Additionally, it may be used NEW METHODS OF INTERNAL DISEASE TREATMENT for the treatment of allergic rhinitis, conjunctivitis, atopic dermatitis.
ESSENCE OF INNOVATION / OC000459 is a selective antagonist of CRTH2 receptors that plays a key role in initiation and maintenance of allergic inflammation.
MARKET POTENTIAL / There are 4 to 8% of population in Russia suffering from bronchial asthma. The prevalence of the disease is increasing, TEAM / especially among children in most of the • J. Moskot - General Director, Clinical countries. It is expected that the shift Study Manager; in the structure of drug utilization will be • A. Alexandrov - Medical Director. from rescue drugs for asthmatic attacks to maintenance (basic) therapy.
CONTACTS / Moscow +7 (495)726 52 53 [email protected]
68 SKOLKOVO GRANT
WDS PHARMA, LLC
NEW ORGANIC GERMANIUM COMPOUNDS TO TREAT HERPES - VIRUS INFECTION
COMPETITIVE ADVANTAGES / • Patentability and commercial priority of new molecules; • Technology «green chemistry»; • Conversion of hydrophobic molecules to hydrophilic organic germanium complexes with high bioavailability and NEW METHODS OF INTERNAL DISEASE TREATMENT less toxicity; • Dual mode of action and improved synergetic efficiency including against resistant strains.
ESSENCE OF INNOVATION / The proprietary core technology platform for chemical synthesis of Germanium and TEAM / different organic substances (including • I. Ambrosov, Ph.D - CEO; various pharmaceutical generics) • Al. Isaev, MD - R&D Director, > 10 years was developed and can be used for experience in synthesis of new organic development of a perspective drugs germanium molecules; in different medicinal therapeutic areas • S. Matelo, MD - CBDO, >15 years (e.g. antiviral, anti-cancer, anti-infection, experience in new products researches, anti-metabolic, immunotherapy etc.) manufacturing, launch, distribution and as well in veterinary, cosmetology, health promotion; care. • J. Buschmann, Ph.D - Head of Toxicology Department in Fraunhofer MARKET POTENTIAL / ITEM (Germany). > 4bln people are infected with herpes viruses worldwide. The global herpes market can reach 9 bln $ to 2018 (CAGR ~10%). Experts says the current market is very generic and looking for new patentable decisions.
CONTACTS / Moscow 1Kulakova str., 20 bld. 1G +7 (495) 781 92 03 [email protected]
69 INFECTEX, LLC
DRUG FOR TUBERCULOSIS WITH MULTIPLE DRUG RESISTANCE TREATMENT
COMPETITIVE ADVANTAGES / High efficacy against DS and DR TB strains. Potential capacity to reduce treatment duration. Synergetic interaction with existing and new anti-TB drug.
NEW METHODS OF INTERNAL DISEASE TREATMENT ESSENCE OF INNOVATION / Both compounds SQ109 and Q203 are highly specific anti-TB drugs with innovation mechanism of action.
MARKET POTENTIAL / Tuberculosis causes enormous economic TEAM / and social damage, affects the working • Y. Delovery - General Director; age population, requires long-term • O. Makeeva - Medical Director; treatment, epidemic control and • Prof. S. Borisov - Scientific Advisor. prevention activities. The Russian Federation government programs for TB treatment cost 5422 mln RUB in 2011.
CONTACTS / Moscow +7 (495) 726 52 53 infoinfectex.ru
70 CARDIONOVA, LLC
INNOVATIVE DRUG FOR HYPERLIPIDEMIA TREATMENT AND ATHEROSCLEROTIC PREVENTION (AHRO-001)
COMPETITIVE ADVANTAGES / TEAM / AHRO-001 decreased intestinal • Zhidkova T. - General Director; cholesterol adsorption, cholesterol • Alexandrov A. - Medical Director. elimination. In preclinical trial it was shown a significant inhibition of atherosclerotic plaques formation(95%)- is a unique therapy effect. NEW METHODS OF INTERNAL DISEASE TREATMENT
ESSENCE OF INNOVATION / The drug molecule (AHRO-001) is a representative of the cholic acids class endogenous components of the bile. AHRO-001 leads to decreasing of cholesterol levels concentration in plasma and reduction of the atherosclerotic plaques.
MARKET POTENTIAL / Market of lipid-lowering drugs is the largest segment of the pharmaceutical market in Russian Federation. Market volume will be worth $2,7 bln in 2018. Importance in «additional» lipid-lowering therapy is quite high in Russia.
CONTACTS / Moscow +7 (495) 726 52 53 infoinfectex.ru
71 HEPATERA, LLC DRUG FOR CHRONIC HBV AND HDV INFECTION TREATMENT
COMPETITIVE ADVANTAGES / The first in class entry inhibitor to treat chronic HBV infection and co-infection with HDV, the desease with no relieble effective standard of care.
ESSENCE OF INNOVATION / Myrcludex B blocks the entry of HBV into NEW METHODS OF INTERNAL DISEASE TREATMENT hepatocytes by binding to and inactivating an essential HBV entry receptor, and thus prevents new hepatocites infection. The intact cells are the depot of the hepatic TEAM / regeneration. • O. Markova - CEO and projects leader; • Y. Delovery - Clinical Trials Coordinator; MARKET POTENTIAL / • A. Alexandrov - Medical Director. The prevalence of HBV (hepatitis B) infection in the world varies from 0,1 to 20 % in different countries, 2-7 % in RF. About 1,1 mln of patients in RF require treatment. The world CHB drugs market is about $3 bln.
CONTACTS / Moscow +7 (495) 726 52 53 [email protected]
72 SKOLKOVO GRANT
SCIENTIFIC AND PRODUCTION ENTERPRISE “HEALTH NAVIGATOR”, LLС
HARDWARE AND SOFTWARE COMPLEX HEALTH NAVIGATOR FOR THE AUTOMATION OF NON-INVASIVE PRENOSOLOGICAL DIAGNOSTICS AND BUILDING UP OF HEALTH RESERVES AND WORKING CAPABILITY OF CHILDREN AND ADULT POPULATION
COMPETITIVE ADVANTAGES / TEAM / The technology allows to give • Orlov V. - General Director; an integrated numerical assessment • Grigoriev A. - Scientific Director; of psychophysical health, as well as • Shpilevoy Y. - Deputy General Director; NEW METHODS OF INTERNAL DISEASE TREATMENT to assess the state of the main • Baranov I. - Technical Director; morphological and functional indicators • Fetisov O. - Business Development and systems of the body, and to have Director. a personalized health-promoting programs for each examined subject.
ESSENCE OF INNOVATION / High-tech automated medical equipment – Hardware and software complex. The complex will dramatically improve the efficiency of the examination, accuracy and reliability of measurements using the technology of Health Navigator.
MARKET POTENTIAL / There are some 30,000 potential consumers in Russia and CIS countries.
CONTACTS / Moscow 2/5 Vysotnyi Proyezd Str. +7 (495) 359 77 66 [email protected] npp-nz.ru/
73 IPHARMA, LLC
INNOVATIVE, BIOSIMILAR, AND GENERIC DRUGS DEVELOPED BY RUSSIAN AND INTERNATIONAL COMPANIES FOR THE PURPOSE OF MARKET REGISTRATION AND WITHIN INTERNATIONAL MULTICENTER STUDIES (PHASE 1-4, BE, REGISTRATION)
COMPETITIVE ADVANTAGES / TEAM / • Development of clinical research • N. Rabinovich, MBA - General Director; programs for innovative drugs from first- • N. Vostokova, PhD - Chief Operating NEW METHODS OF INTERNAL DISEASE TREATMENT in-human studies to market registration; Officer; • Access to top Russian and international • J. Trakhtenberg, MD, PhD - Medical experts; Director; • Scientific and research infrastructure • O. Karavaeva, MD - Director of Clinical of ChemRar: bioanalytics, preclinical Operations; studies, drug formulation development, • K. Semenov, MD - GCP QA Director. clinical series manufacturing.
ESSENCE OF INNOVATION / Complex solutions for organizing and conducting clinical trials within the full cycle of drug development.
MARKET POTENTIAL / • 30+ professionals with vast experience in international and local clinical trials; • Highly qualified management team; • Concurrent conduct of 20+ clinical trials.
CONTACTS / Khimki, Moscow Region +7 (495) 925 30 74 +7 (925) 400 01 33 [email protected] www.ipharma.ru
74 MIP-11, LLC
INNOVATIVE MEDICINES AND CELLULAR TECHNOLOGIES FOR C-TYPE HEPATITIS TREATMENT
COMPETITIVE ADVANTAGES / The product under development, AVR-560 is a new class inhibitor that dramatically differs from all currently known drugs under development against HCV. AVR-560 blocks infection of liver cells at early stages. NEW METHODS OF INTERNAL DISEASE TREATMENT
ESSENCE OF INNOVATION / AVR-560 is an early stage inhibitor of viral genomic RNA. Presumably drugs TEAM / of this class of compounds bind with the • N. Merkin - General Director, with viral non-structural NS4B protein, blocking over 15 years experience in venture the ability of the latter to bind with the business, manages venture projects in viral RNA. Consequently, NS4B protein the fields of innovative pharmaceuticals, loses its ability to deliver the viral RNA to biotechnology, and other. He has replication complexes, where synthesis extensive experience in strategic and of viral RNA occurs. tactical planning, structuring venture capital transactions, financial and MARKET POTENTIAL / business planning, financial management, According to the estimates of organization of new business; DataMonitor, the current volume of 7 • V. Bichko - Science Director, industrial major pharmaceutical markets (US, Japan, scientist of the international level, with Germany, France, Italy, Spain, UK) in 2013 15 years of academic experience in was USD 2.943 billion. However, due research in molecular and cellular biology, to the sales of new high-efficacy drug chemistry, and virology. Dr. Bichko has products and the emergence of treatment extensive experience in working at regimens its rapid growth is predicted. international pharmaceutical companies Peak sales will make over USD 19 billion and bringing drug candidates to clinical in 2016. trials.
CONTACTS / Khimki, Moscow region [email protected] +7 (495) 925 30 74
75 SKOLKOVO GRANT
TRANSLEK, LLC
MODULAR NANOTRANSPORTERS OF ANTICANCER DRUGS
COMPETITIVE ADVANTAGES / Significant enhancement in therapeutic effects of anti-cancer drugs, biodegradability based on the use of recombinant molecules, capability of replacement of modules for alternative diseases and delivery of a wide range NEW METHODS OF INTERNAL DISEASE TREATMENT of anti-cancer substances.
ESSENCE OF INNOVATION / Developing modular nanotransporters (MNT) capable of targeted delivering anti- cancer drugs directly into the nucleus of cancer cells. The technology increases cell specificity and therapeutic effect TEAM / of chemotherapy. • Ulasov A. - General Director; • Sobolev A. - Scientific Director; MARKET POTENTIAL / • Rozenkrantz A. - Senior Researcher. 430,000 cases of bladder cancer and 240,000 cases of brain and nervous system tumours – glioblastoma is the most common, and the most lethal, of these tumours are diagnosed per year (WHO).
CONTACTS / Moscow +7 (926) 581 48 71 [email protected]
76 SKOLKOVO GRANT
REGENEX LLC
THE VACCINE OF AUTOLOGOUS T-REGULATORY CELLS FOR THE TREATMENT OF AUTOIMMUNE DISEASES WITHOUT GENERAL IMMUNOSUPPRESSION
COMPETITIVE ADVANTAGES / TEAM / Lower cost at more effective treatment • Bykovskaya S. - General compared to the standard therapy. Director, Research, MD, professor; No negative systemic effects on the • Nasonov E. - scientific consultant, immune system and no idiosyncrasy, Academician of the Russian Academy typical for traditional immunosuppressive of Medical Sciences, Professor; NEW METHODS OF INTERNAL DISEASE TREATMENT drugs. • Lohonina A. - Researcher, • Zhdanov D. - Senior Researcher ESSENCE OF INNOVATION / employee k.b.n.; A new approach to the treatment • Eliseev D. - Senior Researcher of multiple sclerosis: personalized targeted Associate, MD, neurologist. cell therapy based on the adoptive transfer of autologous T cells. We developed and patented the technology of expansion of T reg with a 1000-fold increase in their number within 7 days. We proved the viability and full functional activity of the duplicated cells.
MARKET POTENTIAL / More than 2.5 million people worldwide suffer from multiple sclerosis. In Russia one accounts for more than 200,000 patients. The annual cost of 1 patient is USD 25,000. in total there are more than 40 million patients with autoimmune diseases. Cellular technology, including the creation of Treg vaccine, is an innovative approach in the treatment of autoimmune diseases, which has no analogues. The planned starting year of commercialization is 2017.
CONTACTS / Moscow +7 (495) 370 56 78 +7 (916) 436 22 91 [email protected] www.roscardioinvest.ru
77 SKOLKOVO GRANT
LABORATORY FOR BIOTECHNOLOGICAL RESEARCH “3D BIOPRINTING SOLUTIONS”
TECHNOLOGY OF THREE-DIMENSIONAL ORGAN BIOPRINTING
COMPETITIVE ADVANTAGES / • All investigations are performed on 3D bioprinter of original construction\design; • “Frameless method” - presents no limits attributable to frame methods of tissue reconstruction (no need in difficult-to- NEW METHODS OF INTERNAL DISEASE TREATMENT obtain frame - leached cadaveric organ or artificial frame); • Ideally, the technology requires autologous stem patient’s cells, thus to eliminate the problem of immune incompatibility. TEAM / ESSENCE OF INNOVATION / • Ostrovsky A. Ph.D (medicine)- General Three-dimensional organ bioprinting could Director; be a solution for millions • Hesuani U. - Executive Director; of people who require reconstruction • Mironov V., Ph.D (medicine) - Scientific or transplantation of defective or entirely Director in the biotechnology research lost organs, as well as well as for immune laboratory; compatibility problems. • Novoselov S., Doctor of Biological Sciences - Head of the research MARKET POTENTIAL / laboratory; The “3D Bioprinting Market, 2014-2030” • Bulanova E. - Head of the cell report provides an extensive study technology laboratory; of the emerging market of complex organs • Mitryashkin A. - Engineer; (kidney, heart, liver), cartilaginous tissue • Smirnova Y. - Director of marketing. (from 131 million US dollars in 2024 year to 3.6 billion US dollars in 2030 year), skin (conservative estimate of skin market alone: 4 310 billion US dollars by 2030 year). In the short term, the agency expects forthcoming results of scientific research work in Drug Testing by 2018 year. Every day, about 17 patients die waiting for surgery in the USA alone, and every 13 minutes a new name appears on the waiting list. Approximately 25-30% of patients perish in the queue for transplantation. Organ deficit remains a global unsolved problem. As at the start of 2014 year, the Laboratory for Biotechnological Research “3D Bioprinting Solutions” was one of 10 private laboratories, who develop own three-dimensional bioprinting technology CONTACTS / and bioprinter of own original construction Moscow and design. +7(499) 769 50 18, PR 5216 ; 5222 [email protected]; [email protected] www.bioprinting.ru
78 SKOLKOVO GRANT
URAL CENTER OF BIOPHARMACEUTICAL TECHNOLOGIES, LLC
HIGHLY EFFECTIVE DRUGS FOR THE TREATMENT OF VIRAL INFECTIONS
COMPETITIVE ADVANTAGES / A broad spectrum and treatment efficacy, high activity against more than 15 specific viral diseases; Effective at any stage of the disease; Lack of side effects and contra-indications; Availability NEW METHODS OF INTERNAL DISEASE TREATMENT of new dosage forms.
ESSENCE OF INNOVATION / We developed a new class of antiviral agents (osalazine) — analogues of purine nucleosides (guanosine). The principle of action is inhibition of synthesis of viral RNA and DNA and replication of genomic fragments. TEAM / MARKET POTENTIAL / • Sorokin P. - CEO; The potential market volume in Russia • Petrov A.- the head of the project; and CIS is RUB 25 billion per year; • Gavrilin A. - Deputy Import replacement in terms of effective Director for Research. antiviral drugs; Scientific advice: Maximum economic benefit by reducing • Charushin V. - Academician of the costs (compared with the price of Russian Academy of Sciences; imported drugs). • Chupahin O. - Academician of the Russian Academy of Sciences; • Rusinov V. - corresponding member. Russian Academy of Sciences.
CONTACTS / Novouralsk Sverdlovsk region [email protected]
79 OPEN SCIENTIFIC SYSTEMS AND TECHNOLOGIES, LLC
HUMAN ARTIFICIAL NERVOUS TISSUE: PHASE II-III CLINICAL TRIAL OF THE MEDICAL TECHNOLOGY OF TISSUE ENGINNERING OF THE SPINAL CORD INJURY (SCI)
COMPETITIVE ADVANTAGES / TEAM / There is no efficient therapy of the SCI • Rodnykh G. - General Director; in the world. This technology has • Bryukhovetsky A., MD, prof.-Neurologist; no analogues. • Kazmin S., Ph.D - Anesthesiologist; • Kovalenko N., PhD- Neurologist; NEW METHODS OF INTERNAL DISEASE TREATMENT ESSENCE OF INNOVATION / • Frolov A., PhD -Neurophysiologist. The equivalent to human nervous tissue based on the matrix SpheroGel was developed by our team and implanted into the spianl cord of a human with SCI.
MARKET POTENTIAL / 15 billion USD: The cost of the surgery in tissue in Russia is 50 000 USD, the number of SCI patients is 600 000. Half of them is eligible for the surgery.
CONTACTS / Moscow +7(499) 713 95 11 [email protected] www.ossat.ru
80 INSTITUTE OF MITOENGINEERING OF MSU, LLC
APPLICATION OF ANTIOXIDANTS WITH DIRECTED ACTION IN MITOCHONDRIA FOR PREVENTION AND TREATMENT OF AGE-RELATED DISEASES
COMPETITIVE ADVANTAGES / The company is integrated into the infrastructure of the Moscow State University. Institute of Mitoengineering of MSU cooperates with leading academic NEW METHODS OF INTERNAL DISEASE TREATMENT institutions around the world and Russia. and has own pharmaceutical production, meeting the GMP requirements, and vivarium experimental complex, meeting the GLP requirements.
ESSENCE OF INNOVATION / The principal technological approach of Project is the creation of active substance, that affects directionally at the mitochondria of cells of living organism TEAM / to regulate the amounts of reactive oxygen • Skulachev I. - Head of the Project; intermediates. Thus it’s possible to prevent • Skulachev V. - Scientific Director; development of diseases associated • Zorov D. - Senior Researcher; with mitochondrial dysfunction, manage • Severin F. - Researcher; the existing diseases and slow down • Skulachev M. - Consultant; the natural aging of the body. • Chernyak B. - Researcher.
MARKET POTENTIAL / • Russian, CIS and USA pharmaceutical markets of eye drops («Dry eye syndrome», glaucoma, cataract, age-related macular degeneration); • Treatment of neurodegenerative diseases and brain pathological states, nephrological diseases; • Medicines for treatment of trophic ulcer; • Anti-age cosmetics.
CONTACTS / Moscow +7 (495) 939 59 45 skq-project.ru
81 MEDBIOPHARM, LLC
EFFECTIVE LOW-TOXICITY DRUG PAM-1 OF DIRECT ANTIVIRAL EFFECT FOR THE TREATMENT AND PREVENTION OF INFLUENZA AND ARVI
COMPETITIVE ADVANTAGES / TEAM / According to the results of preliminary • I. Lenyova, Dr. of Biological Sciences - studies, the drug is 20 times less toxic Head of the laboratory of experimental than its closest analogue, it is superior to virology, FSBI «Scientific Research the analog in efficiency and has Institute of Vaccines and Sera named after NEW METHODS OF INTERNAL DISEASE TREATMENT a therapeutic index greater than 40. I.I. Mechnikov»; • R. Roziyev, Ph.D - Director; ESSENCE OF INNOVATION / • E. Bondarenko, Ph.D - Head of the The drug acts in the early stages of viral department of biomedical research. replication and inhibits the fusion of virus envelope with the lipid membranes of cells, preventing the penetration of the virus into the cell. Biotarget is the surface protein of the hemagglutinin influenza virus (HA). The drug also has interferon- inducing properties, increases the body’s resistance to viral infections.
MARKET POTENTIAL / Main indicators of the Russian market: incidence per year about 40 million people, the volume and growth rate of the market not less than RUB 10 billion with the trend of constant steady growth, the sales potential of RUB 1.5 billion. Main indicators of the world market: incidence per year 500 million people, the market volume of about USD 2 billion.
. CONTACTS / Obninsk, Kaluga region +7 (484) 39 972 58/39 973 38 Fax: +7 (484) 39 658 79 [email protected]
82 ARGONERICA LIFESCIENCE, LLC
SCI(R)-221: BIOADHESIVE GEL WITH PEROXIDE-BASED OXIDATION AGENT FOR TREATMENT AND PREVENTION OF BACTERIAL VAGINOSIS AND ASSOCIATED CONDITIONS
COMPETITIVE ADVANTAGES / TEAM / Member of emerging class of microbiota • S. Derevyannykh - Managing director, modulators, SCI(R)-221 provides for Doctor / MBA, commercialization targeted antibacterial effect required for experience sustained treatment results, particularly innovative pharmaceutical regarding rate of relapses that remains products and Transfer NEW METHODS OF INTERNAL DISEASE TREATMENT unacceptably high with antibiotics. technologies in Russia; • K.Zubovskiy - Scientific Director ESSENCE OF INNOVATION / and President , MD / MBA, 25 years old Innovative patented technology interdisciplinary experience utilizing bioadhesive gel that contains in biopharmaceutical; oxidation agent with confirmed selective • Head microbiomic antimicrobial effect on pathogen bacteria Project , PhD, professor, recognized without negative impact on healthy an expert in the study of vaginal microbiota. microbiota and biofilm.
MARKET POTENTIAL / Based on prevalence data from literature, nearly 10-11 million women in Russia suffer from bacterial vaginosis. At treatment cost of $120 and market penetration of 10%, annual sales are estimated at $30-40 million ($240-300 million in the US).
CONTACTS / Moscow +7 (903) 772 19 87 [email protected] [email protected]
83 CYCLOMEMORIN, LLC
ORIGINAL DRUG PAM-43 FOR THE ELIMINATION OF BRAIN FUNCTIONS VIOLATIONS AND DEMENTIA TREATMENT
COMPETITIVE ADVANTAGES / The drug enhances memory and provides the formation of more stable memory, remaining stable for at least 24 hours after training (analogues — 4-6 hours). The effective dose is much lower than NEW METHODS OF INTERNAL DISEASE TREATMENT that of counterparts (1pM).
ESSENCE OF INNOVATION / TEAM / The drug has a high neuroprotective and • Bachurin S., Doctor of Chemistry, cognitive-stimulating activity. The main RAS Corresponding Member - Scientific mechanism is the potentiation of AMPA Consultant; receptors. It is envisaged the possibility • Bukhman V., PhD - Head of application for treatment of Alzheimer’s of Molecular and Cellular biology disease and other neurodegenerative department, professor at Cardiff University diseases. of Great Britain, Scientific consultant; • Roziev R., MD- Director; MARKET POTENTIAL / • Bondarenko E., PhD- Head Dementia appears in 5% of the population of Biomedical Research department. aged 65 years in the severe form, in 16% in the mild form. The Russian market of nootrophic drugs for the treatment of CNS disorders, associated with decreased cognitive function and memory due to neurodegenerative changes: not less than RUB 6 billion, or 96.6 million units.
CONTACTS / Obninsk, Kaluga region +7 (484) 39 972 58 /39 973 38 +7 (484) 39 658 79 [email protected]
84 SKOLKOVO GRANT
MEDIKON, LLC
VACCINES REDUCING THE PATHOLOGY OF DRUG ADDICTION
COMPETITIVE ADVANTAGES / High efficiency of treatment. Absence of addictiveness and minimum of side effects. Ease of formation of adherence (3-5 boosters per year). Possibility of using test systems «Dianark» to individually control the development of immunity. NEW METHODS OF INTERNAL DISEASE TREATMENT
ESSENCE OF INNOVATION / Fundamentally new approach to the treatment of addiction — vaccine. There TEAM / are no analogs on the world market. The • Myagkova M. -Professor, Doctor use of human proteins instead of “foreign” of Biology, Honored Scientist of RF; ones. Use of the polymer to enhance the • Morozova V. - PhD in chemistry; immune response. • Aristides M. - Consultant, Professor, Doctor of Biological Sciences. MARKET POTENTIAL / The Russian market — 30 million doses per year (60 billion rubles). The global market — 224 million doses per year (14 billion dollars).
CONTACTS / Moscow +7 (495 )673 36 57 +7 (901) 530 53 51 [email protected]
85 BBU PHARMACEUTICALS, LLC
BDG-DOPAMINE — A NEW DRUG FOR PARKINSON’S DISEASE TREATMENT
COMPETITIVE ADVANTAGES / Fast dopamine delivery, Lower side effects, Neuroprotector features - neurons are recovered.
NEW METHODS OF INTERNAL DISEASE TREATMENT ESSENCE OF INNOVATION / BDG-DOPAMINE® — a new Parkinson’s disease drug, enabling direct delivery TEAM / of dopamine to the brain across the • N. Goldstein - Scientific Director, blood-brain barrier (Proprietary delivery professor, doctor of biological sciences; technology). Until recently direct • A. Terterov - CEO; dopamine delivery was considered • N. Nazarov - CIO; to be impossible. • A.Kamenskiy - professor, doctor of biological sciences; MARKET POTENTIAL / • G. Avakyan - professor, doctor BDG-DOPAMINE annual potential of medical sciences. sales — US $40-160 million (10-40% levodopa market). Total market of Parkinson’s disease drug — US $ 2.9-3.4 billion, CAGR - 4.5%.
CONTACTS / Moscow +7 (926) 811 86 61
86 MC DEVELOPMENT, LLC
THE INNOVATIVE DRUG LACTOMEZOLE FOR TREATMENT OF PEPTIC ULCER ASSOCIATED WITH HELICOBACTER PYLORI AND GASTROESOPHAGEAL REFLUX DISEASE (GERD)
COMPETITIVE ADVANTAGES / TEAM / Lactomezol effectively and safely ensure • Mateshonok A. -Development Director; eradication of H.pylori, while reducing • Bordin D. - Doctor of Biological the acid production of the stomach. Sciences, Professor, Medical Advisor; It is promising for the treatment in the • Zakirova S. - Ph.D., Head of Research; presence of polyvalent allergy • Koval A. - PhD, Project manager; NEW METHODS OF INTERNAL DISEASE TREATMENT or intolerance to antibiotics, and in cases • Dorozhko O. - Doctor of Biology, when it is impossible to conduct Project manager; a full anti H. pylori therapy. • Leya M. - Ph.D. professor, foreign consultant. ESSENCE OF INNOVATION / Lactomezol helps to treat gastroesophageal reflux disease and peptic ulcer, wherein eradication of H. pilori will be ensured without intake of antibiotics.Increases the safety of long-term PPI therapy, reduces the risk of development of stomach cancer.
MARKET POTENTIAL / The prevalence of H. pylori by regions of the world in adult population is 90 %. Lactomezol will be able to capture 4% — 6% of the market in the first year since the release of the drug. Lactomezol shows a way to reduce the cost of the eradication cycle as compared with antimicrobial therapy.
CONTACTS / Moscow Skolkovo, Lugovaya str. 4 [email protected]
87 PRIVATE RESEARCH INSTITUTION “THE BIOMEDICAL CENTER”
TEST SYSTEM FOR DIAGNOSTICS OF ONCOLOGICAL DISEASES ON THE BASIS OF A NEW CLASS OF GENES (EVOLUTIONARILY NEW GENES WITH TUMOR-SPECIFIC EXPRESSION) TEAM / COMPETITIVE ADVANTAGES / • Kozlov A. - Director; The test system for the detection • Krukovskaya L. - Senior Researcher; of metastatic cancer of different spectrum • Matyunina E. - Scientific string player. of tumors is based on the measurement of NEW METHODS OF INTERNAL DISEASE TREATMENT the expression level of 48 microRNAs and can identify 25 different types of tumors. Determines a wider range of markers (not only micro RNA) in the earlier stages.
ESSENCE OF INNOVATION / The aim of the project is the creation of a test system for molecular diagnostics of oncological diseases on the basis of the universal genetic oncomarkers. The basis of a markers search is a hypothesis of A.P. Kozlov on the evolutionary role of tumors and prediction of expression of evolutionarily new genes in tumors.
MARKET POTENTIAL / The project implementation will allow to create high-performance multi- functional test system for general diagnosis of cancer. The program is meant within 5 years from the beginning of commercial sales (2020) to achieve the targeted sales volume of the diagnostic prepartion that is over 1.6 billion rubles per year in the Russian market.
CONTACTS / St. Petersburg +7 (812) 499 16 79 [email protected]
88 SKOLKOVO GRANT
PHARMADIALL, LLC
ORIGINAL NEXT-GENERATION ORAL ANTICOAGULANT, DIRECT FACTOR XA INHIBITOR
COMPETITIVE ADVANTAGES / The PharmaDiall developing agent is direct Factor Xa inhibitor, the agent showed the best results in the study of its anticoagulant properties in human blood plasma. NEW METHODS OF INTERNAL DISEASE TREATMENT
ESSENCE OF INNOVATION / The patent-clear chemical compounds showing biologic activity toward Factor Xa TEAM / were developed.The relevant indicators of • Tovbin D. - CEO, Ph.D.; some of the developed compounds are • Tarasov D. - Scientific Director, Ph.D. occurred to be the best in the world.
MARKET POTENTIAL / Pradaxa’s sales may reach $4 billion USD a year by 2020. Xarelto’s sales may peak at more than 2 billion euros a year. We plan total sales about 15 bln RUR for the patent period.
CONTACTS / Moscow +7 (903) 761 27 17 [email protected] www.pharmadiall.com
89 TEARX, LLC
NOVEL ORAL ANTICOAGULANT, WHICH INHIBITS FACTOR XA, FOR THE PREVENTION AND TREATMENT OF THROMBOSIS AND THROMBOEMBOLISM
COMPETITIVE ADVANTAGES / TEAM / According to preclinical and clinical data, • Yakubova E. - General Director; the drug is expected to have a significantly • Konarkovski H. - Director wider therapeutic window comparing Strategic Development; NEW METHODS OF INTERNAL DISEASE TREATMENT to the competitors. • Baranowski S. - Project Manager; • Savitskaya Y. - Business Development; ESSENCE OF INNOVATION / • Zamyatin M. - Scientific Consultant. The drug is an oral highly selective inhibitor of Factor Xa. Binding to the target the TeaRx molecule effectively suppresses blood clot formation without affecting the primary hemostasis. In accordance with the X-ray structure analysis the molecule forms an additional bond with the Factor Xa S1-pocket, which substantially increases the molecule affinity.
MARKET POTENTIAL / New generation anticoagulants is one of the most rapidly growing market segments, which is caused by treatment of previously uncovered groups of patients. The Russian segment just in 4 years has grown up to $53 million. The TeaRx market share is expected to be up to $90 million by 2022.
CONTACTS / Khimki, Moscow region st. Rabochaya, 2a Bldg.1 +7 (495) 925 30 74 Fax: +7 (495) 626 97 80 [email protected]
90 CELL TECHNOLOGIES, LLC
SERUM-FREE MEDIUM FOR CULTIVATION OF MAMMALIAN CELLS
COMPETITIVE ADVANTAGES / TEAM / Most institutions and companies use • Yakimov E. - CEO; premixed dry nutrient medium for the • Chestkov I. - Deputy Director for preparation of the final product, liquid Science. media. This path is not possible to modify the composition of media and conduct research into the development of new SFM. NEW METHODS OF INTERNAL DISEASE TREATMENT
ESSENCE OF INNOVATION / The solution of the problem has largely empirical nature of the search and optimization of the concentration of the limiting components in the medium. However, our experience allows us to organize this search, select the major interest groups metabolites, bind the individual parameters of cell metabolism to their needs as part of a serum-free medium.
MARKET POTENTIAL / This project aims to develop a SFM for the Russian market. Access to the mar- kets of Asia will be possible after imple- mentation of this phase, and then will require an establishment of a small, but new for Russia production of powdered culture media. Global trends suggest growth in produc- tion of culture media, primarily due to increased production of SFM. We did not meet the objective assessment of the Russian market in attitude of culture media, and the market SFM in Russia has not yet formed. On the basis of indirect estimates, Russia imports currently powdered media and their components for the production of about 100 tons of liquid media a year. With expansion of the use SFM to 20% of the market, the total value of the SFM is not less than 300 thousand dollars a year.
CONTACTS / Moscow +7 (926) 558 34 31 [email protected] +7 (916) 908 14 98 [email protected]
91 BIND RUS, LLC
NEW CLASS OF HIGHLY SELECTIVE TARGETED AND PROGRAMMABLE ONCOLOGY / IMMUNOLOGY THERAPEUTICS CALLED ACCURINSTM
COMPETITIVE ADVANTAGES / Accurins are highly selective medicines that target and accumulate at the site of disease, resulting in enhanced efficacy and reduced side effects. Accurins represent the first targeted and programmable nanomedicine to reach the clinic and demonstrate clinical anti-tumor activity.
ESSENCE OF INNOVATION / BIND’s Medicinal Nanoengineering® platform enables the design, engineering TEAM / and manufacturing of Accurins and BIND RUS is a wholly owned subsidiary is compatible across a broad range of BIND Therapeutics Inc. (Cambridge, of small molecule-based drugs, including MA, NASDAQ: BIND). In close molecularly targeted agents such collaboration with BIND Therapeutics, as kinase inhibitors and other classes BIND RUS creates and develops new of therapeutics. best-in-class therapeutics. • Elmira Safarova, PhD - General Director. MARKET POTENTIAL / BIND’s Medicinal Nanoengineering® platform enables the design, engineering and manufacturing of Accurins and is compatible across a broad range of small molecule-based drugs, including molecularly targeted agents such as kinase inhibitors and other classes of therapeutics.
CONTACTS / Moscow Nauchny proezd, 20 bld 2, 117246 Russia +7 499 645 52 23 [email protected]
92 NATIONAL BIOSERVICE, LLC
THE FIRST IN RUSSIA COMMERCIAL RESEARCH BIOBANK ONCOLOGY / IMMUNOLOGY AND BIOSERVICE, THAT COMBINES THE REPOSITORY OF BIOLOGICAL SAMPLES AND ASSOCIATED INFORMATION WITH A WIDE RANGE OF BIOSERVICES
COMPETITIVE ADVANTAGES / TEAM / • Broad clinical profile of the biobank; Team members have long record • Centralized multi-discipline services; of successful commercial and academic • Rapid biospecimen collection; projects in biomedical field, accumulated • Quality of service (QMS); in UK, the Netherlands, USA, Sweden, • Strict adherence to the law and highest Italy, Germany and Russia. ethical standards; • Operational flexibility and competence; • Competitive prices.
ESSENCE OF INNOVATION / Providing Russian and international customers with a wide range of services focused around biobanking and bioservice - namely, biospecimen sourcing, molecular and cellular biology studies.
MARKET POTENTIAL / Biospecimens and associated services world market has reached $1.3 bln by 2012 and $1.9 bln by 2014; it is believed to reach $2.3 bln by 2015 and $2.8 bln by 2018.
CONTACTS / Saint-Petersburg 17a Litovskaya Str., Bldg.A +7 (812) 603 26 09 [email protected] www.nbioservice.com
93 SKOLKOVO GRANT
NEWVAC, LLC
NOVEL ORAL HISTONE DEACETYLASE INHIBITOR FOR THE TREATMENT ONCOLOGY / IMMUNOLOGY OF ONCOLOGICAL DISEASES
COMPETITIVE ADVANTAGES / TEAM / The drug has no marketed competitors. • Yakubova E.- General Director; • Konarkowski H. - Alliance Manager; ESSENCE OF INNOVATION / • Baranovskiy S. - Project Manager; The drug is an oral histone deacetylase • Savitskaya Y.- Business Development inhibitor. The inhibition of histone Manager; deacetylase results in hyperacetylation • Fedianin M.- Scientific Advisor. of histones providing altered expression of oncogenes and tumor supressors, thereby reducing proliferation and inducing apoptosis.
MARKET POTENTIAL / Resulting from the high prevalence of non- small cell lung cancer and ovarian cancer, quisinostat sales in Russia are estimated to reach $80 mln by 2021.
CONTACTS / Khimki, Moscow region 141400, st. Working , 2a Bldg.1 +7 (495) 925 30 74 Fax: +7 (495) 626 97 80 [email protected]
94 AUTOFARM, LLC
DRUG BASED ON THE IMMUNOGLOBLIN INTEGRATED COMPOUND ONCOLOGY / IMMUNOLOGY AND TROPHOBLASTIC SS-1-GLYCOPROTEIN FOR THE TREATMENT OF AUTOIMMUNE DISEASES AND THE ORGANIZATION OF ITS SERIAL PRODUCTION
COMPETITIVE ADVANTAGES / In the proposed project remedy betaglobulin based on TBG and immunoglobulin complex preparation (ICP) is not an immunogen for humans, has no toxicity and can be administered to people many times. TBG suppresses exacerbation of autoimmune diseases. The cost of betaglobulin preparation in the proposed project for the treatment of per TEAM / patient with autoimmune disease in the • Bylov K. - General Director; year will be around 1000 dollars.USA. Now • Antonyan R. - Head of Research; for treatment of rheumatoid arthritis drug • Loktev D. - Deputy General Director; Remicade is used. The cost of treatment • Martynova E. - Head of preclinical and per patient per year is 12 800 dollars USA. clinical trials; • Rusakov V. - Chief Engineering Officer. ESSENCE OF INNOVATION / This method allows providing manufacture from plasma of donor blood the complex immunoglobulin preparation (IgG+IgA+IgM) with better characteristics on immunoforetic purity, the amount of antibodies, to solubility and percentage yield of a ready preparation from raw materials. The aim of the project is development of industrial technology manufacture the remedy for treatment of autoimmune diseases based on the immunoglobulin complex preparation and TBG from donor and retroplacentary plasma in different medicinal forms: capsular, suppository.
MARKET POTENTIAL / Russia in 2010, according to Pharmexpert, for drug procurement under the program «7 nosologies» the government spent 45 illion rubles RUB.
CONTACTS / Moscow, Zelenograd +7 (964) 712 99 97 [email protected]
95 SKOLKOVO GRANT
FUSION PHARMA, LLC
ONCOLOGY / IMMUNOLOGY NOVEL TYROSINE KINASE INHIBITORS AS POTENTIAL ANTICANCER DRUGS
COMPETITIVE ADVANTAGES / PF-114 is effective against all known resistant mutated forms of Ph+ leukemias and possesses improved selectivity profile.
ESSENCE OF INNOVATION / PF-114 is a targeted drug, next generation Bcr-Abl inhibitor for treatment of Ph+ leukemias. Efficacy of PF-114 was demonstrated in in vitro and in vivo models of chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia, including most resistant disease forms with T315I mutation. High safety profile of PF-114 was confirmed in in vivo TEAM / toxicology studies. • G. Chilov, PhD - General Director; • F. Novikov, PhD - Head of Pre-clinical MARKET POTENTIAL / Development; PF-114 potentially can occupy up to one • I.Titov - Head of Medicinal Chemistry; third of global market of resistant Ph+ Advisory board comprising 9 worl-leading leukemias. clinicians in the field of Ph+ leukemias, representing USA, Germany, Italy, Japan, Australia.
CONTACTS / Moscow 2, bld. 18, General Dorokhov str. +7 (495) 933 60 80 [email protected]
96 SKOLKOVO GRANT
NOMOTECH, LLC
DIFFERENTIAL ANALYSIS ONCOLOGY / IMMUNOLOGY OF ONCOMUTATIONS IN SATURATED DNA SAMPLES (DAOSS) FOR EARLY NON-INVASIVE CANCER DIAGNOSTICS
COMPETITIVE ADVANTAGES / DAOCS technology increases sensitivity and reliability of cancer mutation detection and decreases its cost. In pilot experiments, reliable detection of a single mutant DNA molecule was possible against the background of more than 100,000 molecules without mutation.
ESSENCE OF INNOVATION / Our approach is based on a novel NGS library preparation method and a special TEAM / bioinformatic algorithm. This combination • A. Zaretsky - Head of Assay design opens the way to near-absolute & validation; elimination of PCR and NGS errors – and • D. Shagin - Head of R&D; hence to ultrasensitive detection of cancer • I. Volchenkov - Bioinformatics/software; mutations. • T. Panfilov - CEO. Advisory Board: MARKET POTENTIAL / • S. Lukyanov, Full RAS Member; Clinical market entry – planned in 2016. • N. Zhukov, Head of Clinical Oncology Department, FSCC PHOI n. a. Dmitry Rogachev.
CONTACTS / Moscow 117997, st. Maclay, d. 16/10, Bldg. 15 +7 (495) 988 40 83 [email protected] www.nomotech.ru [email protected]
97 SKOLKOVO GRANT
NATIONAL PHARMACEUTICAL TECHNOLOGIES, LLC
SMALL MOLECULE WITH NOVEL THERAPEUTIC TARGET ONCOLOGY / IMMUNOLOGY AND POTENTIAL APPLICATIONS IN ONCOLOGY
COMPETITIVE ADVANTAGES / TEAM / Drug candidate acts on a new kinase • Chilov G., PhD, - General director; therapeutic target, which causes • Stroganov O. - Senior scientist; suppression of migration and invasion • Titov I. - Head of medicinal chemistry. of tumor cells and unlocking of apoptosis Tumor biologists from Russian oncology mechanisms. center; Glasgow University, UK; ESSENCE OF INNOVATION / Saga University, Japan. Our target is tyrosinkinase that regulates expression of matrix metalloproteases, cytosceleton remodeling, and protects tumor cells from apoptosis.
MARKET POTENTIAL / Drug candidate can be used in combination with cytotoxic drugs agains non small cell lung cancer, colorectal cancer, breast cancer, ovarian cancer and other tumors, with total demand 118 ths pts/year in Russia).
CONTACTS / Moscow +7 (916) 307 48 42 [email protected]
98 SKOLKOVO GRANT
ONCOTARTIS, LLС
PORTFOLIO OF ANTI-CANCER DRUGS ON A BASIS OF AN ORIGINAL ONCOLOGY / IMMUNOLOGY DRUG-DISCOVERY CONCEPT OF “PHARMACOLOGICAL SURGERY”
COMPETITIVE ADVANTAGES / The main competitive advantage of the drugs developed is their ability to completely eliminate primary tumor cells as well as cells of the secondary metastases.
ESSENCE OF INNOVATION / A new approach to anti-cancer drug search on the basis of pharmacological therapy concept, which will provide the possibilities for solving such problems as the treatment of recurrent tumors and drug-resistant TEAM / cases. A success realization of the project • Prof. A. Gudkov - Founder and CSO; will lead to a real breakthrough in treatment • Dr. A. Polinsky - Founder and President; of major malignances. • Dr. A. Leonov, CEO; • Dr. K. Andrianova - Business MARKET POTENTIAL / Development; The world market of anti-cancer drugs • Dr. D. Kazyulkin - Head of Medicinal exceeds U.S. $ 100 Billion. The products Chemistry. developed by the company will help Partners: Roswell Park Cancer Institute to treat up to 40% of all registered types (Buffalo, New York,USA). of cancer.
CONTACTS / Moscow Stoloviy per., D. 6, p. 2 +7 (495) 974 74 01 (ext. 171) [email protected]
99 SKOLKOVO GRANT
RUSSIAN PHARMACEUTICAL TECHNOLOGIES, LLC (INNOVATIVE COMPANY RUSPHARMTECH)
ONCOLOGY / IMMUNOLOGY RPT835, LOW-MOLECULAR INHIBITOR OF FIBROBLAST GROWTH FACTOR RECEPTOR 2 IN THE CANCER TREATMENT
COMPETITIVE ADVANTAGES / RPT835 is one of the first allosteric inhibitors in oncology.Principle benefits of allosteric inhibitors: high specificity; low toxicity; cells with mutations sensitive to treatment; different isoforms of receptor could be targeted. TEAM / • Tjulandin S. - Head of the Project; ESSENCE OF INNOVATION / • Timofeev IV -Project Consultant; RPT835 decrease activity of FRFR2 by • Byakhov M. - Project Coordinator, binding an allosteric site at the receptor • Tsimafeyeva T. - General Manager. (that is, a site other than the receptor’s active site), without affecting other mechanisms, can increase the effectiveness of therapy and reduce its toxicity.
MARKET POTENTIAL / Research is carried out on applying RPT835 to treat common cancers: gastric cancer, triple-negative breast cancer, endometrial cancer, colorectal cancer, papillary renal cell carcinoma.
CONTACTS / Saint-Petersburg +7 (812) 454 40 55 +7 (812) 937 29 65 www.ruspharm.com [email protected]
100 METAMAX, LLC
INNOVATIVE BIOPHARMACEUTICAL DRUGS BASED ON P16 ONCOLOGY / IMMUNOLOGY PEPTIDE- CDK INHIBITOR TO TREAT TUMORS RESISTANT TO CLASSIC CHEMOTHERAPY AGENTS (INCLUDING COLORECTAL CANCER, PANCREATIC TUMORS AND OTHERS)
COMPETITIVE ADVANTAGES / Target therapy with cell death activation; selectivity to tumor cells; cytotoxic agent delivery without biomembrane alteration; synergetic effect with known cytostatics.
ESSENCE OF INNOVATION / MM-D37K is a «chimeric» peptide. It consists of a transport sequence (responsible for cell penetration) and cytotoxic amino acid sequence responsible for tumor cell death.
MARKET POTENTIAL / TEAM / Market size till 2017 year (7 major • Plekhova L. - CEO markets): gastro-intestinal tumors project manager at clinical stage; $7,8 billion; pancreas tumors $ 1 billion; • Bozhenko V. - Ph.D., Researcher glioma - $ 0.3 billion. Market size growth Counsellor, Head of the Laboratory is due to morbidity increase and new cellular technologies in Oncology therapies launch. FGU Russian Research cents Radiology Medical University.
CONTACTS / Moscow +7 (495) 726 52 53 [email protected]
101 SKOLKOVO GRANT
INCURON, LLC
ONCOLOGY / IMMUNOLOGY INNOVATIVE СURAXIN-BASED PHARMA PRODUCTS FOR TREATING ONCOLOGICAL DISEASES
COMPETITIVE ADVANTAGES / Curaxins affect several targets within a tumor cell limiting its drug resistance capability and increasing the efficiency of tumor growth suppression. Curaxins are applicable for recurrent courses due to the lack of genotoxicity.
ESSENCE OF INNOVATION / Curaxins block activity of the chromatin remodeling complex FACT (FAcilitates Chromatin Transcription) and in relation to that simultaneously influence several cell signaling pathways (р53, PI3K/AKT/ mTOR, NF-kB, HSP) with disrupted regulation in cancer cells. TEAM / MARKET POTENTIAL / • Leonov A.,PhD - CEO; Oncological diseases take a prominent • Shpigotskaya P., M.D., Ph.D, - Director place in the morbidity and mortality of Clinical Development; ratings. The number of patients grows • Purmal A., PhD - Head of U.S. office. annually due to the aging of population in developed countries. The market share of targeted antitumor medicines reaches as high as 65-70%.
CONTACTS / Moscow 6 Stolovy pereulok +7 (495) 974 74 01 [email protected] www.incuron.ru
102 SKOLKOVO GRANT
IMPEDANCE MEDICAL TECHNOLOGIES, LLC
PERSONALIZED ELECTRICAL IMPEDANCE TOMOGRAPHY ONCOLOGY / IMMUNOLOGY SYSTEM FOR DIAGNOSTICS OF BREAST PATHOLOGIES
COMPETITIVE ADVANTAGES / The average price of a multi-frequency electrical impedance mammograph is RUB 600,000. The price of a device being developed for personalized instant diagnostics is expected to be RUB 10,000–13,000, which will make it affordable for widespread use.
ESSENCE OF INNOVATION / The mammograph hardware will become an optimized portable version of the multi-frequency electrical impedance mammograph (MEM) manufactured TEAM / nowadays combined with a built-in expert • Smirnov A.- CEO computation module. PROJECT PARTNERS: • Institute for Radio Engineering and MARKET POTENTIAL / Electronics of RAS; Breast cancer is annually diagnosed • Yaroslavl State Medical Academy. in nearly 1mln of women worldwide. There is a need for development of a method enabling early non-invasive breast pathology diagnostics at home, which is affordable to the majority of women.
CONTACTS / Yaroslavl’ off. 41, 90 Oktyabrya prospekt, +7 (4852) 58 13 23 +7 (4852) 90 08 32 +7 (4852) 91 37 77 +7 (915) 985 25 25 [email protected]
103 MEDVIO EURASIA, LLC
ONCOLOGY / IMMUNOLOGY DENDRIVAX ANTICANCER VACCINE BASED ON DENDRITIC CELLS WITH A NEW GENERATION ADJUVANT
COMPETITIVE ADVANTAGES / The novelty of the approach is to activate dendritic cells (DCs) in situ and to use allogeneic cell adjuvant that stimulates a cytotoxic T-cell response, which reduces the costs and increases the effectiveness of the vaccine.
ESSENCE OF INNOVATION / Development and introduction into clinical practice of DendriVax immunotherapeutic vaccine based on DCs with a new generation adjuvant for treatment of hormone-resistant prostate cancer and other solid tumors. TEAM / MARKET POTENTIAL / • Egorov O. - CEO; A real alternative to chemotherapy will • Oschepkov B. - Medical Director; appear in the market for treatment of • Baldueva I. - Head of Production stage III-IV prostate cancer, increasing Laboratory; life expectancy and improving patients’ • B. Tjoa - Expert for Production; quality of life. • W. Kavanagh - Expert for Clinical Trials; • Dr. M. Kiselevsky, Prof., - Scientific Advisor.
CONTACTS / Moscow st. Ordzhonikidze, d. 11, p. 2 [email protected]
104 A-VAK, LLC
NON-INDIVIDUALIZED METHOD OF SPECIFIC IMMUNOTHERAPY ONCOLOGY / IMMUNOLOGY OF MALIGNANT SOLID TUMORS
COMPETITIVE ADVANTAGES / The key differences of the product from existing solutions and new products: • The possibility of mass production; • High efficiency for many types of solid malignant tumors; • The possibility of tumor development prevention.
ESSENCE OF INNOVATION / The proposed product is developed as a non-individualized vaccine that is suitable for treatment of various forms of solid tumors. TEAM / • Krylov O. - Chief Executive Officer; MARKET POTENTIAL / • Amirov R. - Deputy General Director; Mass production of PRAV vaccine will • Poletaev A. - Chief Scientific Officer; lead to treatment accessibility for many • Gantsev S. - Senior Consultant for types of solid tumors. PRAV vaccine Oncology; which is under development will have • Brendberg A. - Consultant for Molecular global competitiveness. Research. Partners: CJSC «Management Company «Savings and Investments».
CONTACTS / Moscow st. Rustaveli Str. 3, k. 7, Apt. 9 [email protected]
105 SKOLKOVO GRANT
RUSGENDIAGNOSTICS, LLC
IMPLEMENTATION OF TECHNOLOGY FOR EARLY DIAGNOSIS, ONCOLOGY / IMMUNOLOGY SELECTION OF INDIVIDUAL DRUG COMBINATIONS AND PERSONALIZED MEDICINE IN ONCOLOGY IN RUSSIA
COMPETITIVE ADVANTAGES / The developed diagnostic system will allow: • Excluding the costs for the therapy known to be ineffective, • Avoiding selection of drugs by trial and error method, • Increasing effectiveness of oncology patients’ treatment.
ESSENCE OF INNOVATION / System diagnostics and personalized TEAM / selection of the optimal cancer treatment • Nikolskaya T. - CEO; will allow to detect numerous defects • Serebriyskaya T. - CSO, Head of the in a tumor, and at the same time to project; analyze them using proprietary technology • Tjulandin S. - Head of Clinical trials in the automatic mode. in the project; • Fedyanin M. -Associate of the Clinical MARKET POTENTIAL / trials in the project. The diagnostic system will be available in three versions that will differ in cost and type of diagnostics, a doctor and a patient will be able to choose the most appropriate one.
CONTACTS / Khimk, Moscow Regioni [email protected]
106 SKOLKOVO GRANT
ONCOMAX, LLC
DRUG BASED ON A MONOCLONAL ANTIBODY FOR THE ONCOLOGY / IMMUNOLOGY TREATMENT OF ONCOLOGICAL DISEASES (OM-RCA-01)
COMPETITIVE ADVANTAGES / OM-RCA-01 is a highly selective and high-affinity monoclonal antibody blocking FGFR1, new target antigen involved in the oncogenesis. It is able to inhibit cancer growth by more than 90%. No analogous have been developed yet for this actual target.
ESSENCE OF INNOVATION / OM-RCA-01 blocks one of the major signaling pathways of angiogenesis by FGFR1binding, preventing its interaction with the stimulating fibroblast growth factor. OM-RCA-01 - a humanized antibody having low immunogenicity and TEAM / toxicity. • Ivanova E., Ph.D. - General Director; • Timofeyev I. - Scientific Advisor, the MARKET POTENTIAL / inventor; The market segment including diseases • Alexandrov A. - Medical Director. where FGFR1-dependent angiogenesis plays important role for diseases progression (breast cancer, and prostate and kidney metastatic cancer, NSCLC) is over $ 25 billion.
CONTACTS / Moscow +7 (495) 726 52 53 [email protected] www.oncomax.ru
107 OSTEROS BIOMEDICA, LLC
DRUG PRODUCT FOR THE TREATMENT OF TUMOR-INDUCED BONE ONCOLOGY / IMMUNOLOGY LESIONS (MBC-11)
COMPETITIVE ADVANTAGES / MBC- 11 inhibits the process of metastatic lesions and at the same time improves the condition of the bone tissue. Targeted delivery and release of active agents in the bone to reduce the dosage, improve portability and increases the effectiveness of therapy.
ESSENCE OF INNOVATION / MBC-11 is chemically synthesized unique conjugate of two molecules – TEAM / bisphosphonate and chemotherapeutic • Ivanova E., Ph.D - General Director; agent. First component provides the target • Karpeisky A., D.Sc. - Chief Scientific delivery of conjugate into bone destruction Officer; site and the second one destroy bone- • Zinnen Sh., Ph.D. - Chief Development associated tumor cells. Officer.
MARKET POTENTIAL / The median survival of patients with bone metastasis ranges from 6 to 48 month depending on kind tumor. More than half of such patients have skeletal- related events: severe pain, pathologic fractures, compression of spinal cord. Such complications do not only reduce the quality of life, but also significantly increase the cost of the treatment. The volume of the target market is $ 5.5 billion.
CONTACTS / Moscow +7(495) 726 52 53 [email protected]
108 ONCOMETRIX, LLC
DEVICE FOR HIGH-VALUE INSTANT DIAGNOSIS ONCOLOGY / IMMUNOLOGY OF PROSTATE CANCER BASED ON THE ANALYSIS OF PROSTATIC SECRETIONS AND EJACULATE
COMPETITIVE ADVANTAGES / The developed product will be in demand on the market at the time of commercialization due to the considerably higher sensitivity and lower price. There are no Russian and foreign analogues of this test.
ESSENCE OF INNOVATION / The levels of certain biomarkers of non- protein origin are measured in the prostatic secretions and/or ejaculate. The sample is evaluated using colorimetric, enzymatic and electrochemical methods. TEAM / • Rossmann M., PhD - Head of the MARKET POTENTIAL / project; The developed test can replace the PSA • Soloviev D., Ph.D - Scientific Director; test and drive the latter out of the market • Soltamova I. - General Director; of prostate cancer diagnostics both in • Shashkov A., PhD - Commercial Russia and abroad. Director; • Istvan Boros, PhD - Intellectual Property Development; • Usov S. - Business Consultant.
CONTACTS / St. Petersburg 191014, st. Rebellion 30/7, Bldg. A, of. 11-H +7 (812) 635 75 44 [email protected] www.camonx.com
109 ONCOBIOMARKER, LLC
NEW METHOD OF EARLY DIAGNOSTIC OF MALIGNANT EOPLASMS ONCOLOGY / IMMUNOLOGY
COMPETITIVE ADVANTAGES / TEAM / ELI-Onco-Test differential-diagnostic • Krylov O. - CEO; multicomponent test system under • Amirov R. - Deputy General Director; development will make it possible • Poletaev A. - Chief Scientific Officer; to identify cases of malignant tumor • Gantsev Sh. - Principal Consulant in growth regardless of anatomical Oncology; localization and histological nature, that is, • Brendberg A. - Consulatnt of Molecular will be universal. The test system is based Research. on synthetic peptide fragments of tumor- associated antigens, the cost of which is many times lower than that of both natural antigens and recombinant antigens used by authors of competing solutions.
ESSENCE OF INNOVATION / Use the autoantibody panel for screening and detection of oncopathologies in the early stages of the disease
MARKET POTENTIAL / It is assumed that already in the next 3-5 years high confidence detection of early marker changes can become an effective diagnostic tool, suitable for mass medical examination of the population, and aimed at detection of cancer in the early stages of its development. Onсobiomarker Company can create a segment in the market of the Russian Federation and in other countries with a dominant share.
CONTACTS / Moscow Ap. 9, Bldg 7, Rustaveli Str. 3, [email protected]
110 SKOLKOVO GRANT
QUANTUM AGE, LLС
ANTICANCER DRUG WITH NEW MECHANISM OF ACTION - ONCOLOGY / IMMUNOLOGY INHIBITION OF PHOSPHOFRUCTOKINASE PFKFB3 (INHIBITOR OF CANCER METABOLISM)
COMPETITIVE ADVANTAGES / • Broad applicability in variety fo cancers; • Minimum of adverse reactions; • Not expensive manufacturing; • Efficiency for treatment of solid tumors; • Application as a drug of first-line treatment; Stratification of patients and biomarker for quick response measurement.
ESSENCE OF INNOVATION / The ability of the developped drug to affect one of the most important molecular TEAM / mechanisms linked with oncogenesis - • Fedichev P. - CEO; glycolityc nutrition which determines • Kholin M. - Deputy General Director; possible wide anicancer action of the drug. • Pyrkov T. - Scientific Researcher; • Eremeeva T. - Scientific Researcher; MARKET POTENTIAL / • Shishov D. - Scientific Researcher; The annual sales of the succesful broad • Kadushkin A. - Head of Chemical anti-cancer drug can be above 5 bln USD. Department.
CONTACTS / Moscow st. Cosmonaut Volkov 6A , of. 1205 +7 (499) 156 15 61 www.q-pharm.com [email protected]
111 ANDRUS REO, LLC
LAUNCHING OF ORIGINAL ANTITUMOUR DRUG BASED ON REO VIRUS ONCOLOGY / IMMUNOLOGY
COMPETITIVE ADVANTAGES / TEAM / • Confirmed efficacy and safety of the Management company and shareholder product, that several times exceed RVC Biofund Ltd. existing solutions; • High level of selectivity; • Final stage of product development, high level of successful registration; • Comprehensive protection of IP; • Product is licensed from Canadian public biotech company; • Safety of base concept (wild virus strain) over competitors’ genetically modified solutions; • Consent of the developer to all-round support for the project on the territory of RF and CIS.
ESSENCE OF INNOVATION / Drug has been developed on the base of one of the strains of reovirus that actively prolifirates inside cells with gene regulating cells proliferation (Ras) and kills them. Prolifiration cycle continues in cancer tissue till virus faces healthy cells that can stand against infecting. Very high level of safety.
MARKET POTENTIAL / Russian market is estimated at $50 mln annually, market scope of metastatic head and neck cancer therapy is sized up to whole head and neck cancer therapy market.
CONTACTS / Moscow + 7(495) 788 80 92 [email protected]
112 SKOLKOVO GRANT
QUANTUM PHARMACEUTICALS, LLC
DEVELOPMENT OF DRUG CANDIDATES AGAINST HIV/AIDS ONCOLOGY / IMMUNOLOGY ON THE BASE OF INHIBITORS OF THE HIV MATRIX PROTEIN MA/P17
COMPETITIVE ADVANTAGES / • New mechanism of action inhibition of the HIV1 MA/p17 protein; • High conservatism of the selected protein; • Decreased risk of resistance; • High level of efficacy; • Low toxicity.
ESSENCE OF INNOVATION / The development may become a novel highly potent approach to treat HIV/ADIS especially considering the task of creating a small molecule compound active against TEAM / drugresistant HIV strains, with low • Fedichev P. - CEO; toxiсity, and convenient dosing. • Kholin M. - Deputy General Director; • Pyrkov T. - Scientific Researcher; MARKET POTENTIAL / • Eremeeva T. - Scientific Researcher; The annual sales of the succesful anti-HIV • Shishov D. - Scientific Researcher; drug with new mechanism of action can • Kadushkin A. - Head of Chemical be above 1 bln USD. Department.
CONTACTS / Kosmonavta Volkova str., 6A, of. 1205 +7 (499)156 15 61 www.q-pharm.com [email protected]
113 SKOLKOVO GRANT
NATIONAL INNOVATION INSTITUTE, ANO
NEW MEDICATION FOR TREATMENT OF ONCOLOGICAL DISEASES ONCOLOGY / IMMUNOLOGY OF THE HUMAN REPRODUCTIVE SYSTEM
COMPETITIVE ADVANTAGES / TEAM / High DIM bioavailability in the drug, • Kiselev V; allowing to build up effective active drug • Alakhov V; ingredient concentrations in lesions • Khasanov R; High active drug ingredient selectivity • Frank G. to transformed cells, manifested by extremely low toxicity Multifocal action, simultaneous impact on several critical tumor growth mechanisms.
ESSENCE OF INNOVATION / Cezarox is the first antineoplastic drug to have a selective inhibiting activity with respect to tumor cells (ovarian cancer) and low toxicity. A guarantee of drug effect implementation in vivo (in clinical trials) is high bioavailability when the active drug ingredient concentration will reach 10 µМ and more.
MARKET POTENTIAL / Anticancer drugs, Drug therapy of iatrogenic complications of chemotherapy tumors. Introduction Tsezaroksa a standard treatment (this will The first original domestic medicament for the treatment of oncological diseases ) will allow take a decent position in the its segment with a total capacity of at least 120-140 mln.
CONTACTS / Moscow +7 (495) 989 45 93 [email protected] www.anonii.ru
114 ASPERA, LLC
NEXT GENERATION THERAPEUTIC CANCER VACCINES ONCOLOGY / IMMUNOLOGY
COMPETITIVE ADVANTAGES / Higher efficacy, affordability, versatility, TEAM / simpler administration and supply. • Tsyrenov L., Ph.D., MBA -Founder & CEO; ESSENCE OF INNOVATION / • Rin Sano - Qualified pharmacist; Next generation cancer vaccines utilizing • Hiroshi Shiku, M.D., Professor, Mie nanogel delivery system and full length University School of Medicine -Scientific antigen proteins with wide epitope Advisor., founder of Japanese biotech spectrum inducing strong immune company ImmunoFrontier LLC; response without expensive • Naozumi Harada, Ph.D - Scientific personalization. Advisor.
MARKET POTENTIAL / Priced at $6000/treatment course of 6 injections (17-20 times cheaper than existing marketed vaccine) world market capacity for our vaccines is up to $25 bln. Russian market potential is about $770 mln.
CONTACTS / Moscow [email protected] +7 (983) 423 43 35 +81-80-4795-2512
115 INNOVATIVE PHARMACOLOGY RESEARCH (IPHAR), LLC
DEVELOPMENT OF AN R&D СENTER OF PRE-CLINICAL ONCOLOGY / IMMUNOLOGY AND CLINICAL TRIALS AND IMPLEMENTATION OF PROJECTS OF INNOVATIVE DRUG DEVELOPMENT FOR RUSSIAN AND GLOBAL MARKET
COMPETITIVE ADVANTAGES / IPHAR’s R&D center performs a wide range of drug development activities: from preclinical and clinical trials to technology transfer to the manufacturer’s facility. IPHAR is a coordinating center ensuring project implementation and commercialization.
ESSENCE OF INNOVATION / The drugs under development have a novel mechanism of action, high safety and efficacy, can be used to treat TEAM / cardiovascular, neurodegenerative, mental, The company employs a team infectious, oncologic, endocrine and other of specialists, which has 6 D.Sci. diseases. and 12 Ph.D., including: • V. Khazanov, Dr.Med.Sci., professor - MARKET POTENTIAL / President; 4-8 billion RUB per year (Russian market), • N. Belskaya, Dr.Med.Sci - Preclinical up to $300-400 million in the global Trials Department; market through sale of licenses. • K. Nurmukhametova, Ph.D. - Pharmaceutical Development Department; • V. Larchenko, Ph.D. - Clinical Trials Department; • S. Stankevich, Ph.D. - Project Director.
CONTACTS / Tomsk 79/4 ul. Elizarovykh 634021
116 TIATSEN, LLC
ORIGINAL DRUG - RHODANINES PAM-14 DERIVATIVE ONCOLOGY / IMMUNOLOGY FOR TREATMENT OF ONCOLOGY DISEASES
COMPETITIVE ADVANTAGES / An order lower toxicity, compared with other antitumor agents, with validly pronounced therapeutic effect. There is a supposed efficacy in the treatment of tumors of various etiologies, as well as in the occurrence of resistance of tumor cells to existing antitumor drugs. TEAM / ESSENCE OF INNOVATION / • Roziyev R., Ph.D. in M.Sc. - Director; The drug is a specific blocker • Shtil A.,Dr. of Medicine - Head of serine-threonine proteinkinase GSK3β, of the Laboratory of Tumor Cell Death hyperactivity of which is associated with Mechanisms, N.N. Blokhin RCRC; the formation of tumors. Incubation with • Bondarenko E., Ph.D. in B.Sc., - Head the drug significantly inhibits the growth of the Department of Biomedical of a culture of tumor cells, reducing their Research; viability according to the MTT assay. • Dzhugashvili M. - Leading Specialist in Radiation Oncology, Madrid Institute MARKET POTENTIAL / of Oncology. Annually in Russia about 500 thousand cancer patients are revealed, at least 80% of them need treatment with chemotherapeutic drugs and/or radiation therapy. The volume of the Russian market for cancer drugs is about RUB 45 billion with the tendency of constant steady growth.
CONTACTS / Obninsk, Kaluga region +7(484) 39 972 58 /39 973 38 (484) 39 658 79 [email protected]
117 118 CONTACTS CLUSTER 119 TEAM
Kirill Kaem VICE-PRESIDENT, EXECUTIVE DIRECTOR
e-mail: [email protected] tel: +7 (495) 956-00-33, ext. 2584
Yuri Nikolsky SCIENCE DIRECTOR
e-mail: [email protected] tel: +7 (495) 956-00-33, доб. 2210
Evgeny Tkachenko KEY PARTNERS DIRECTOR
e-mail: [email protected] tel: +7 (495) 956-00-33, ext. 2528
Yulia Gulenkova HEAD OF FORESIGHT: MEDICAL PRODUCTS&EQUIPMENT, HEALTHCARE IT
e-mail: [email protected] tel: +7 (495) 956-00-33, ext. 3007
Alexey Strygin ANALYST OF MEDICAL DEVICES/CLINICAL IT PROJECTS
e-mail: [email protected] tel: +7 (495) 956-00-33, ext. 2258
120 Sana Kagermazova ANALYST OF NEW METHODS OF INTERNAL DISEASE TREATMENT PROJECTS e-mail: [email protected] tel: +7 (495) 956-00-33, ext. 2242
Kristina Khodova HEAD OF ONCOLOGY/IMMUNOLOGY PROJECTS e-mail: [email protected] tel: +7 (495) 956-00-33, ext. 2522
Kamila Zarubina ANALYST OF ONCOLOGY/IMMUNOLOGY PROJECTS e-mail: [email protected] tel: +7 (495) 956-00-33, ext. 2042
Victoria Kazbekova Аssistant e-mail: [email protected] tel: +7 (495) 956-00-33, ext. 2364
121 122 INDEX OF PROJECTS 123 А G 3D Bioprinting Solutions 78 HemaCore Labs 28 Avkor 39 Hepatera 72 А-ВАК 105 Alpha Biotech 37 Angio Lab 64 Andrus Reo 112 Argonerica Lifescience 83 Aspera 115 Н Autofarm 95 Aelita 23 Health Modelling Technology 53 Allied Innovations 29 Health monitoring 50 AllCardio 57 Health Navigator 73 B Berikon 44 I BBU Pharmaceuticals 86 Biomedical Center 88 IK Sovremennie tehnologii 21 BioConstructor-S 67 Incuron 102 Biosten 36 Innovative Technologies 42 BioTechnology 32 Intro-Micro 47 BioNova 26 Infectex 70 Biosoft 24 Innovative Pharmacology 116 Bind rus 92 Institute of Mitoengineering of MSU 81 Research (IPHAR) Impedance medical 103 technologies 74 C Ipharma 58 Integracia CardioNova 71 Cryoton 48 Cyclomemorin 84 Cell Technologies 91 L Laboratory of innovations 34 D Luminescence Diagnostics Instruments 31 Data MATRIX 45 GeNext 43 JoinTechCell 60 М Е Medbiopharm MedIAToma 82 Eleventa 68 Medvio Eurasia 41 European Center of Development Medikon 104 for Innovations (ECDI) 35 Medel 85 MetaMax 49 Millisecond Technologies 101 MIP-11 27 MC Development 75 F Motorica 87 Medical Technologies of Belgorod 51 FM Diagnostics 52 State University 54 Functional NPO 40 Fusion Pharma 96
124 N R NIIRM (Scientific and Research 38 Receptor 30 Innovative Developments Regenex 77 of Medical Devices) R&D Intercell, LLC 46 National Innovation Institute 114 Rusgendiagnostics 106 National BioService 93 RusBITech 19 NeuroMax 65 Ruspharmtech 100 Nomotech 97 NSL 22 NewVac 94 National Pharmaceutical Technologies 98 S
Sante Farm Semiotik 66 Siberian Water Technologies 59 О Simbiotech 55 56 OnCobiomarker 110 OncoMax 107 Oncometrix 109 OncoTartis 99 Osteros Biomedica 108 Т Open Scientific Systems 80 and Technologies TheraMAB 63 TeaRx 90 Tiatsen 117 Translek 76 P 33 PrimeBioMed 25 Photonics 61 Pharma Bio 89 U PharmaDiall 20 PharmaSapphire Ural Center 79 of Biopharmaceutical Technologies Q Quantum Age 111 Quantum 113 Pharmaceuticals W WDS Pharma 69
V 62 Valentech
125